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Prostate cancer is the most common cancer among men. The purpose of this quantitative, 
meta-analysis study was to examine one-carbon metabolism gene polymorphisms in a 
group of genes to determine their association with prostate cancer risk. The genetic 
epidemiology theory provided the framework for the study. The data collected were from 
published articles. From over 2,800 individual studies, 20 articles were retained for 
results and data abstraction, following the title, abstract screen, and full text screening in 
the second phase. The data were analyzed by a meta-analysis statistical method, 
combining the results from selected studies to estimate the overall association. According 
to study results by the adjusted p-values of fixed model, there was a significant 
association between decreased risk of prostate cancer and the variant of Allele T, 
Genotype TT, and the recessive model of C667T polymorphism. In the random model, 
the adjusted p-values show a significant association between decreased risk of prostate 
cancer, the variant of Genotype TT, and recessive model. There was an increased risk of 
prostate cancer in A1298C polymorphism by adjusted p-value on the variant of Genotype 
AC, in the fixed model. This study leads to positive social change by providing 
information on an optimization surveillance strategy to ensure valid screening test for 
prostate disease reporting. Future studies with a greater number of samples are needed, 
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Chapter 1: Introduction to the Study 
Introduction 
Researchers have pointed out the association between genetic factors and 
diseases, especially cancer (Gibson et al., 2011). Many scholars have identified gene-
disease association at the first level of study (Ponder, 2001). However, there is not an 
appropriate sample size in an individual study to analyze this genetic disease association. 
In this study, I used a meta-analysis statistical method to increase the power of the test by 
the summary of effect size estimation. The selected genes, including their 
polymorphisms, were MTHFR (C667T, A1298C), MTR (A2756G), and MTRR (A66G). 
In this chapter, I will highlight the background of gene-disease association, including the 
problem statement on prostate cancer risk plus research questions. This chapter will 
include the theoretical framework with the assumptions, limitation, and scope. In this 
chapter, I will indicate the purpose of this quantitative meta-analysis on the combination 
of multiple studies’ results to determine the association of one-carbon metabolism gene 
polymorphisms and prostate cancer risk.  
Background of the Study 
Prostate cancer should be a health concern for all males. Prostate cancer was the 
second leading cause of death among men in the United States in 2009 (“CDC - Prostate 
Cancer,” n.d.). In the United States in 2009, 206,640 males were diagnosed with prostate 
cancer and 28,088 males died from prostate cancer (“CDC - Prostate Cancer,” n.d.). The 
mean age of males diagnosed with prostate cancer decreased from late 1990s, and the 




2003). The rate of new prostate cancer among males in the United States, by race or 
ethnicity, is the highest among African American males. The incidence rate per 100,000 
males for all races is 156.9; in a subcategories by race, it is 226.0 for African Americans, 
145.1 for European Americans, 121.6 for Hispanic Americans, 78.2 for Asian Americans, 
and 71.7 for Native Americans (“CDC - Prostate Cancer,” n.d.). The heritability of 
prostate cancer is high, as the first-degree relative of males with prostate cancer have two 
to three times the chance of developing the disease (Evans, Metcalfe, Ibrahim, Persad, & 
Ben-Shlomo, 2008). 
More than 1,000 researchers have reported an association between prostate 
cancer, with single nucleotide polymorphism (SNPs), and other genetic variants, in which 
the genome-wide association (GWA) studies identified replicated the association 
(Gudmundsson et al., 2009). One-carbon metabolism gene polymorphisms are involved 
in the folate metabolic pathway (Bailey & Gregory, 1999). There is a growing body of 
evidence that one-carbon metabolism gene polymorphisms are related to cancers such as 
colorectal cancer, breast cancer, and lung cancer (Suzuki et al., 2008; Suzuki et al., 2007; 
Theodoratou et al., 2012). Theodoratou et al. (2012) reported the risk factors of one-
carbon metabolism gene polymorphisms and colorectal cancer. Suzuki et al. (2008) 
determined the effect of one-carbon metabolism related gene polymorphisms on breast 
cancer, and Suzuki et al. (2007) studied the effect of one-carbon metabolism related gene 
polymorphisms in lung cancer. Collin et al. (2009) examined the folate pathway of gene 
polymorphisms with the risk of prostate cancer and meta-analysis methodology. Eussen 




Zhang et al. (2012) analyzed MTHFR polymorphism and prostate cancer risk. 
Researchers found that polymorphisms in the gene-encoding methylenetetrahydrofolate 
reductase (MTHFR) may impede homocysteine remethylation (Wojcieszynska, Hupert-
Kocurek, & Guzik, 2012). Wojcieszynska et al. (2012) also found a mutation of C677T 
polymorphism has a frequency of 0.32 in the European American population, which the 
homozygous (T677T) of this mutation has about 30%-35% of the normal MTHFR 
activity. There is a gap in the literatures regarding a potential association between 
MTHFR, MTR, and MTRR genes with prostate cancer risk. The gap is due to small 
sample size in prior studies that reduced the power of the tests. The interrelationship 
between MTHFR genotype, riboflavin, and folic acid showed in Figure 1. The riboflavin 
and folate can protect individuals against loss of function of MTHFR and can reduce the 










The relationship between riboflavin status and plasma total homocysteine (tHcy) 
concentration is confined mainly to subjects with the T-allele, but not in subjects with the 
C677C genotype. Jackson et al. (2013), one of selected subjects for this systematic 
review, reported an interaction between levels of folate and prostate cancer but found no 
interactions between genotype and folate concentration. In general, Jackson et al. 
reported a weak MTHFR (A1298C) effect on low-grade prostate cancer. 
Descriptive Epidemiology 
There are different methods of preventing cancer risk, such as screening, which 
serves to prevent cancer by detecting precancerous lesions. Cancer is defined as abnormal 
cells that divide uncontrollably that are able to invade other tissues. There are risk factors 
related to cell abnormality such as age, ethnic group, and family history, that may 
increase the likelihood of genetic mutation due to gene-environment and gene-gene 
interaction (Grönberg, 2003). In the etiology of prostate cancer, researchers have 
suggested that the Vitamin E and beta-carotene may affect the development of prostate 
cancer (Heinonen et al., 1998). In a study of Alpha-Tocopherol intake by male smokers 
in Finland, Heinonen et al. (1998) showed a 32 % decrease in the incidence of prostate 
cancer and a 41% lower mortality among males with prostate cancer than those taking the 
placebo and not receiving alpha tocopherol. Heinonen et al. found a reduction in clinical 
prostate cancer, but not in latent cancer. Klein et al. (2011) examined the long-term 
effects of Vitamin E in a defined population in the United States, Canada, and Puerto 
Rico and concluded that dietary supplementation with Vitamin E increased the risk of 




The genetic epidemiology of prostate cancer is related to endogenous hormones, 
including both androgens and estrogen hormones. In studying prostate cancer risk, Ross 
et al. (1998) indicated the role of genetic variation in androgen biosynthesis and 
metabolism. The androgen receptor (AR), amino acid named CAG, which repeat length 
in Exon 1, may relate to prostate cancer risk. There are prostate cancer-associated genes 
in the length of the polymorphic CAG repeat in androgen receptor gene (AR) greater than 
or equal to 20 repeats (Gu, Dong, Zhang, & Niu, 2012). The purpose of this systemic 
review was to evaluate the risk of prostate cancer on the evidence of SNP-based 
genotyping panels of three one-carbon metabolism gene polymorphisms (MTHFR, MTR, 
and MTRR) in the quantitative literature. 
A polymorphic in an allele is a variation in DNA if it occurs in at least 1% of the 
population (Feero, Guttmacher, & Collins, 2010). Feero et al. (2010) also indicated that 
SNP are variations in the DNA sequence that occur about once in every 800 base pairs. In 
this study, I examined a group of genes named one-carbon metabolism gene 
polymorphisms: MTR (5-methyltetrahydrofolate-homocysteine methyltransferase), 
MTRR (5-methyltetrahydrofolate-homocysteine methyltransferase reductase), and 
MTHFR (methylenetetrahydrofolate reductase).  
The MTR gene is located on the long (q) arm of Chromosome 1 at position 43. 
The MTR gene is in the structure of an enzyme called methionine synthase. This enzyme 
plays a role in processing amino acids in a particular methionine synthase, which perform 




methionine (López-Cortés et al., 2013). The variant of MTR (A2756G) may increase the 
risk of cancer (Jackson et al., 2013). 
The MTRR gene is located on the short (p) arm of Chromosome 5 at location 
15.31. The MTTR gene provides instructions for making methionine synthase reductase, 
which it is for the proper function of the methionine synthase enzyme (Watkins et al., 
2013). This enzyme can continue to produce methionine. Without methionine synthase 
reductase, the cycle of synthesis cannot convert homocysteine to methionine (National 
Center for Biotechnology Information [NCBI], 2014). The variant of the MTRR (A66G) 
gene may be associated with an increased risk of cancer (Jackson et al., 2013). 
The MTHFR gene is located on the short (p) arm of Chromosome 1 at location 
36.3. The MTHFR gene making methylenetetrahydrofolate reductase enzymes, which 
involves a chemical reaction of the B-vitamin folate, also called folic acid or vitamin B9 
(NCBI, 2014). In the description of the enzyme, methylenetetrahydrofolate reductase, it 
converts 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The mutation of 
changes in single amino acids (677C>T) in methylenetetrahydrofolate reductase causes 
inactivated (turned off) the enzyme (NCBI, 2014). The mutation can increase the risk of 
cancer (López-Cortés, 2013). 
Prostate Cancer Screening 
The aim of this meta-analysis was to summarize the results of previous studies 
and evaluate the evidence of an association between one-carbon metabolism gene 
polymorphism and prostate cancer risk, due to prostate cancer genetic screening. It is the 




Cancer screening program is used to test cancer in individuals, to evaluate 
asymptomatic people in the community, and to detect an unsuspected disease or risk due 
to improved health outcomes. Prostate cancer screening occurs in two ways: by prostate-
specific antigen test (PSA) of the blood sample and the digital rectal exam (DRE). The 
prostate cancer screening is a program for monitoring progression in patients who are 
involved in prostate cancer risk, the process approved by the U.S. Food and Drug 
Administration (FDA) in 1986 (Rao, Motiwala, & Karim, 2008). According to Ilic, 
O’Connor, Green, and Wilt (2011), prostate cancer screening does not have a statistically 
significant mortality difference between those males who are randomized to screening 
and the control group. In addition, there is no an indication that age is a risk factor for 
participants who are screened for prostate cancer mortality. Early prostate cancer 
screening is beneficial as males have a life expectancy of less than 10-15 years once 
diagnosed (Ilic et al., 2011). 
Some people fear mandatory genetic tests or prostate cancer genetic screening, 
which may reduce the right of privacy and potentially leading to discrimination (Fulda & 
Lykens, 2006). In addition, some people fear genetic testing of predictive diseases, like 
prostate cancer, because employers or the insurance company may absolve their financial 
responsibility for treating prostate cancer. The employer would not wish to hire a person 
with prostate cancer because they do not wish to pay increased medical or sick day 
benefits. The insurance company for individuals with prostate cancer may reduce 




Ethically, some family members may not wish to be informed of the positive test’s result, 
as the disease would be an inherited disease.  
The primary disadvantage of screening is the high rate of false-positive results for 
a PSA test. There is also the risk of infection, bleeding, and pain in trans rectal 
ultrasonography guide biopsies (“CDC - Prostate Cancer,” (n.d.). The rate of the PSA test 
reducing mortality rates remains unclear, and Canada no longer recommends the PSA test 
as a population-based screening test (“Canadian Cancer Statistics Publication,” n.d.). The 
purpose of this study was to better understand genetics and its relationship to diseases, 
including how to able to prevent the disease by establishing a policy and treatment 
procedures. The results of this study may help health professionals to determine one-
carbon metabolism gene polymorphisms as a risk for prostate cancer. This study will lead 
to positive social change by providing health care workers information on how to better 
diagnose prostate cancer at the early stages and how to follow a sufficient treatment 
approach. Treatment of prostate cancer at an early stage will increase the chance of 
surviving and life expectancy in the community (Woods, Montgomery, Herring, Gardner, 
& Stokols, 2006).  
Policy Implications 
Public health policies are used to promote health and prevent diseases and to 
reduce the morbidity and mortality in the population. Policymakers need to make policies 
to address public health outcomes. Policymakers may use the results of this study to 
improve health care delivery for patients with prostate cancer. Policymakers must create 




with prostate cancer disease control. In epidemiologic studies, researchers have indicated 
the association between occupational exposure to pesticides to an increased risk of 
prostate cancer (Maele-Fabry & Willems, 2003). Maele-Fabry and Willems (2003) found 
a significant increase in the prevalence of prostate cancer for both private (farmer) and 
commercial applicators. Legislative policies need to improve the prevention and control 
of prostate cancer through efficient genetic cancer screening.  
Key Stakeholders 
Cancer of the prostate is the second leading cause of cancer death in males in the 
United States and Canada (“Canadian Cancer Statistics Publication,” n.d.). One out of 
seven Canadian males will develop prostate cancer in their life (“Canadian Cancer 
Statistics Publication,” n.d.). In this systematic review, I increased awareness of the 
symptoms of prostate cancer and provided insight into the potential barriers to treatment 
for males who are at an increased risk for prostate cancer. A genetic test is an effective 
way to decrease the risk of prostate cancer, including the prognosis of prostate cancer at 
an early stage to an effective treatment strategy. This study could lead to improved 
genetic screening for prostate cancer and provide information on how males at risk of 
developing prostate cancer can adopt a healthy lifestyle. Health professionals can use the 
concept of genetic analysis to find ways to protect men from prostate cancer by using 
surveillance techniques and increased accurate genetic tests. Policymakers may establish 
a policy to develop genetic screening regarding developing a healthy lifestyle for 





Prostate cancer includes abnormal cells that grow out of control in a male’s body; 
prostate cancer is the most common cancer. Prostate cancer is the second leading cause of 
cancer death among males (Muslumanoglu et al., 2009). Gene mutation can cause 
prostate cancer. Researchers have found that one-carbon metabolism-related gene 
polymorphisms are related to cancers, such as colorectal cancer (Theodoratou et al., 
2012), breast cancer (Suzuki et al., 2008), and lung cancer (Suzuki et al., 2007). One-
carbon, metabolism-related gene polymorphisms are a group of genes, but, in this study, I 
was interested in following three genes MTHFR, MTR, and MTRR (Gibson et al., 2011). 
The one carbon metabolism gene polymorphisms are involved in the folate metabolic 
pathway (Bailey & Gregory, 1999). 
In this study, I examined the association between genes and prostate cancer risk. 
The purpose of my study was to fill the gap in the literature in identifying the association 
between prostate cancer and one-carbon metabolism gene polymorphisms, MTHFR 
(C667T, A1298C), MTR (A2756G), and MTRR (A66G). There were three previous 
studies on this subject with smaller samples of the test than I had in this study. A unit in a 
meta-analysis test is an individual study, which will increase the number of individual 
studies in a meta-analysis (samples), and the power of the test will increase (Borenstein, 
Hedges, Higgins, & Rothstein, 2009). In my study, the number of individual studies 
included in the analysis will be almost twice the number of individual studies than 




One assumption for a meta-analysis is the independence between included studies 
in the analysis. One of a previous meta-analysis study (Zhang et al., 2012) included the 
results from a previous meta-analysis as an individual study, which departed from this 
assumption. I used a meta-analysis statistical process regarding the weighting strategy by 
combining the results of individual independent studies from previous researches from 
the year 2000 to the year 2014 (Borenstein et al., 2009).  
I used two concepts of epidemiology in this study to examine cancer genetic 
epidemiology and epidemiological methods. In cancer genetic epidemiology, I studied 
the cause of cancer and its related risk factors to prostate cancer, including gene variants 
of one-carbon metabolism gene polymorphisms in prostate cancer (López-Cortés et al., 
2013). In this epidemiological method, I used a statistical method of analysis to combine 
the results of multiple studies with a common hypothesis to determine a significant 
association. The goal of this study was to identify genetic risk factors related to prostate 
cancer risk in the early stage of the disease and to determine an appropriate treatment 
method. The results of this study may be used to inform treatment methods to treat 
prostate cancer in the early stage of the disease. 
Purpose of the Study 
The aim of this meta-analysis, a quantitative study, was to summarize the results 
of previous studies and evaluate the evidence of an association between one-carbon 
metabolism gene polymorphism and prostate cancer risk. It is the value of mutant genes 
(SNPs) in the detection and prediction of prostate cancer risk. The independent variables 




dependent variable was prostate cancer risk among men. The covariates were regions and 
ethnicity groups. 
Research Questions and Hypotheses 
The research question regarded the examination of the relationship between one-
carbon metabolism gene polymorphisms and prostate cancer risk.  
1. Is there any significant association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk? 
H10: There is no association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
H1A: There is an association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
2. Are there any significant differences between regions of the globe due to 
gene-disease association? 
H20: There are no differences between regions due to gene-disease association. 
H2A: There is a difference between regions due to gene-disease association. 
3. Are there any significant differences between ethnic groups due to gene-
disease association? 
Null Hypothesis H3o: There are no differences between ethnic groups due to gene-
disease association. 





The region in this study was an independent variable to determine its association 
with prostate cancer risk. People in different regions have different ancestry, which is 
important in a population genetics study. The ancestry carries a set of genes, which are 
common for those groups of the people. Those specific genotypes in the ethnic groups 
make a different phenotype for them, which may affect their lifestyle and risk factors for 
prostate cancer, such as nutrient intake and healthy activity. The regions in this study 
were in three groups of continents: the Americas, Europe, and Asia. The ethnic groups 
were in four groups of Caucasian, Caucasian-African American, Caucasian-Spanish, and 
Asian. 
Theoretical Framework 
Theories and models are used to improve the interventions targeted to improve 
health behavior and create a positive change in behavior. The theories are a set of 
interrelated concepts used to explain and predict phenomena by specifying relations 
among variables (Coreil, 2010). The most successful public health programs are those 
that include theories of health behaviors. In social epidemiology, the basis of the theory is 
on society and biology. Social epidemiology is a connection of sociological frameworks 
that provide a basis for epidemiological inquiry by defining the role of societal factors in 
the etiology of disease (Krieger, 2001).  
The social determinant of health theory includes the genes that are related to 
health outcomes, such as genes and biology, physical environment, social environment or 
social characteristics, health behaviors, and health services or medical care (“CDC - 




et al. (2003) incorporated health theories to improve public health by assessing the 
relationship between prostate cancer and one-carbon, metabolism gene polymorphisms, 
and the causation and association of genes and cancer. Some researchers examined the 
association between genetics, disease, and associated risk factors such as diet (Cai et al., 
2010). Some of these scholars looked at the relationship between prostate cancer and risk 
factors like age, race, alcohol consumption, and environment (Kobayashi et al., 2012). In 
some of those studies, there was no improvement in the creation of theoretical 
frameworks to refine the association between genes and prostate cancer. 
In this study, a genetic epidemiology with a multiple level approach was the 
major theoretical framework, in which human genomics and mutated gene determination 
are the way to promote health benefits and improve population health.  
The quantitative method was used to determine the measure of variables, as well 
examine the statistical relationships between them. The quantitative tradition was used to 
help me examine how genes may affect prostate cancer.  The results of this study could 
help to understand the relationship between genes and prostate cancer with other 
variables such as age, race, education, family history, and geographical situation 
(Creswell, 2009, pp. 57-61). Ancestral region may also be related to an increased risk of 
prostate cancer risk due to genetic variation among regions of people (Grönberg, 2003). 
Genetic Epidemiology 
In order to understand disease prevention, public health workers must know 
human genomics (NCBI, 2014; Figure 2). Human genomics can be used to determine 




may use genetic epidemiology to examine a gene's role in the health of a population by 







Figure 2. Synergy of public health actions in addressing the role of genomics in 




According to genetic epidemiology, a gene disease is associated with a multiple 
level approach. The multilevel approach includes individual behavior changes by 
improving the knowledge of prostate cancer genetic screening; the interpersonal level as 
friends and familily levels are affected by prostate cancer. At the organization level, 
males may benefit from an improved health status by improving the affordability and 
accessibility of genetic screening. At the community level, the health in the community 
could be improved by promoting cancer genetic screening, and at the public policy level, 
recommendations could be made to establish genetic screening regimins and policies 
(Coreil, 2010). 
Nature of the Study 
There is a reported relationship betweeen one-carbon metabolism gene 
polymorphisms and cancers such as colorectal cancer, breast cancer, and lung cancer 
(Suzuki et al., 2008; Suzuki et al., 2007; Theodoratou et al., 2012). The purpose of this 
meta-analysis study design was to increase the power of the test in gene-disease 
association by increasing the sample size. The purpose of this quantitative, meta-analysis 
study was to test whether there was a relationship between genetic factors and prostate 
cancer risk (Creswell, 2009, p.132). I used a deductive approach to improve the study of 
prostate cancer. The data were collected from published articles. The collected data 
combined other researchers’ study results who examined the relationship between one-
carbon metabolism gene polymorphisms and prostate cancer. Specifically, the plan of this 
study was to estimate the relationship between risk factors of genes associated with a risk 




analysis in this study was based on a meta-analysis method with combining the odds 
ratios of selected studies to make an overall effect size (odds ratio). This meta-analysis 
helps to make a higher statistical power to measure the gene and prostate cancer 
association than selected individual studies. The independent variables included three 
genes (MTHFR, MTR, and MTRR) and their four polymorphisms of the one-carbon 
metabolism gene polymorphisms. The dependent variable was the risk of prostate cancer. 
The covariates of analysis were geographical areas as regions and ethnic groups. The 
regions were coded in three groups of continents: Americas, Europe, and Asia. The ethnic 
groups were in four groups of Caucasian, Caucasian-African American, Caucasian-
Spanish, and Asian. 
Definitions 
Meta-analysis: A statistical method used to combine the results of different 
studies to make an overview of the effect sizes, resulting in a  higher statistical power of 
the test than an individual study. 
MTHFR Gene: The methylenetetrahydrofolate reductase (MTHFR) with two 
polymorphisms of 677C>T (rs1801133) and 1298A>C (rs1801131; NCBI, 2014). 
MTR Gene: The 5-methyltetrahydrofolate-homocysteine methyltransferase gene 
(MTR) with polymorphism of 2756 A>G (rs1805087; NCBI, 2014). 
MTRR Gene: 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 




Prostate cancer: A cancer that occurs in a male organ (prostate). The prostate is a 
reproductive organ, which adds fluid and nutrients to the sperm. It is about the size of a 
walnut in front of the rectum below the bladder (“CDC - Prostate Cancer,” n.d.). 
Assumptions 
In this meta-analysis, the data collection process was based on identifying, 
selecting, appraising, and extracting results from relevant research (Yach, 1990). In this 
epidemiological method, a quantitative analysis method was based on study gene variants 
and one-carbon metabolism gene polymorphisms that related to prostate cancer risk. In 
all of the selected studies, the researchers employed a valid statistical analysis to 
determine the effect size of the association between genes and prostate cancer risk. In this 
study, I amassed large amounts of data from different studies with a common hypothesis. 
In the combined studies’ statistical analysis (meta-analysis), there was a higher power of 
the test than what was included in the individual study, considering the growth of the 
sample size. The assumptions that I made in this study were similar to the assumptions 
made in the individual studies with the same criteria, which I selected. The assumption of 
this meta-analysis was independence between selected studies, and each study had the 
same inclusion and exclusion criteria with other selected studies. The selected studies 
should be independent because the result of the individual study added to the 
combination of studies’ results. As an example, if a study included a result from a 
combination of four studies’ results, which each one of those studies already involved 




would be included in the final result twice, one as an individual study and one as 
combined with other studies.  
Scope and Delimitations 
The data gathered were based on published individual studies from the year 2000, 
which was the year that the genetic clinical tests improved, to the year of 2014. The intent 
of this study was to estimate the association between one-carbon metabolism gene 
polymorphisms and prostate cancer risk. The gene disease association is an important 
subject in recent clinical studies. The focus of this study was on prostate cancer risk 
among men because prostate cancer is the second leading cause of death among men in 
the United States (“CDC - Prostate Cancer,” n.d.). I also examined the effect of regions 
and ethnic groups on the gene-disease association. The included populations were those 
men who were at risk of prostate cancer as a case group, and they were selected by 
researchers who conducted individual studies. The case group was compared to those 
healthy men as a control group. The delimiting factors come from environmental factors, 
and the study-by-study included variables, such as a folate intake variable. The collected 
studies were from across the globe. The delimitation of the analysis method is on the 
range of variables that included an individual study to measure the gene-prostate cancer 
association. The theory was on genetic epidemiology based on a gene-disease association 
with a multiple level approach. The multilevel includes individual behavior, interpersonal 
level, organization level, community level, and the public policy level recommendations 




Validity is indicated as follows: the ability to generalize the results in the real 
world using a measurement strategy, the ability to generalize the results from the 
measurement and the study design, and the ability to determine that the results are 
accurate. The validity of the study  refers to the researcher being able to answer the 
questions with the variables included to the studies (Reis & Judd, 2000). In this meta-
analysis, the validity increased by including comparative studies that met the inclusion 
criteria with high quality and similar methods and same variables.  
Internal validity relates to causal relationships (Hogg & Cooper, 2007; Reis & 
Judd, 2000). Internal validity was the ability to measure observed prostate cancer risk, 
which should be void of systematic error and biases. The internal validity included the 
lab results for the gene validation (genotyping) of the three involved genes (MTHFR, 
MTR, and MTRR) in this study. To meet external validity, a study’s result should be 
generalizable to other related populations (Reis & Judd, 2000).  This study met external 
validity by identifying those men who were at risk of prostate cancer by the genotyping 
method. Although this study selected the samples from men who were in the population 
boundaries by researchers, the samples were from men around the globe. In this study, 
the validity of the statistical conclusions will improve by examining both the fixed and 
random effects models. 
The reliability of a study is related to the quality of measurement: its repeatability 
and consistency of the measurement (Hogg & Cooper, 2007). In this study, the quality of 
measurement related to the laboratory methods of gene mapping for the three gene 




the diagnoses of prostate cancer, were affected by the quality of measurement. The 
measure of prostate cancer risk would be based on two methods: chemicals and physical 
exams. The relationship of validity and reliability is based on the consistency and 
repeatability of the measurements. The consistency of the same or a close result in all 
repeated measurements will make it a reliable and valid measure. 
Limitations 
This investigation was limited to the information included in the studies in the 
meta-analysis. This information lacked a systematic study review. In the identification of 
individual studies, I developed research questions to examine the association between 
prostate cancer and the identified genes. This study was limited to a human genome study 
and an SNP analysis of the human population. The language of reviewing articles was 
limited to English, unless there was a translation of non-English article to the English 
language. A limitation to internal validity was the way variables were measured in 
individual selected studies that may have varied slightly. The type of variables measured 
were identical for all of the selected studies. External validity may have been limited by 
the inability to generalize the results because of the lack of an adequate sample size for 
the cases of study (men with prostate cancer) in the globe.  
There also were three limitations on selected articles: search bias, publication 
bias, and selection bias. The search bias may have occurred in identifying relevant issues, 
as some researchers may have missed some of the related research. A study with a 
positive result, which is usually in favor of a new treatment or against a well-constituted 




have occurred because principals such as drug manufacturers are not interested (mostly) 
in publishing negative studies (Walker, Hernandez, & Kattan, 2008). There may have 
beeen a limitation of a Type I error if there was correlation among the four 
polymorphisms. In the future studies, the gene-gene and gene-environment interaction 
related to the cancers with common genes’ risk factors should be distinguished. 
Significance of the Study 
Through this study, I could help public health workers provide an early diagnosis 
method for prostate cancer. This study can help clarify the role of genetic factors in 
determining the likelihood of developing prostate cancer. The results of this study may be 
used to better understand genetics and its relationship to diseases, as well as how to be 
able to prevent the disease by providing more effective treatment strategies. This study 
could aid health professionals to recognize one-carbon metabolism gene polymorphisms 
as a risk factor for prostate cancer risk. This study could lead to positive social change by 
providing health workers with more information on the diagnosis of prostate cancer in the 
early stages, including a sufficient treatment approach using gene therapy, which could 
increase the chance of surviving by adopting a healthy lifestyle.  
Summary 
In this chapter, I highlighted the concept of this study including the nature of 
study and problem statement based on a multilevel theoretical model. I  provided the 
overview of gene and prostate cancer association. The research question of this study was 
based on an evaluation of the association between one-carbon metabolism gene 




method, which will be explained in detail in Chapter 3. In this chapter, I explained and 
addressed the epidemiology of prostate cancer and cancer genetic screening benefits. 
Genetic screening for breast cancer and colorectal cancer do help to diagnose the disease 
at an early stage and reduce the morbidity and mortality (Hugosson et al., 2010). In 
summary, prostate cancer genetic screening (genotyping) could help health care workers 
to diagnose this disease at an early stage of the disease. Prostate cancer genetic screening 
could be used to diagnose the disease at an early stage and could help to establish 
effective treatment strategies to prevent prostate cancer development. Chapter 2 is the 





Chapter 2: Literature Review 
Introduction 
In Chapter 2, I review the literatures related to the subject of prostate cancer, one-
carbon metabolism gene polymorphisms, and the association between them.  
Literature Search Strategy 
In this section, I review how I found the literature for the meta-analysis. I explain 
my search strategy and inclusion and exclusion criteria. I describe how I looked for o 
one-carbon metabolism gene polymorphism where there is an explanation of three 
involved genes: MTHFR, MTR, and MTRR (Gibson et al., 2011). To find pertinent 
articles on my topic, I used the following databases: EMBASE, MEDLINE, Index 
Medicus, and WaldenU database. The key words used for the search were cancer, 
prostate cancer, one-carbon metabolism, MTHFR, MTR, MTRR, genetics, genomics, 
gene, one-carbon, epidemiology, genetic epidemiology, systematic review, cohort, case 
control, and cross section. I started the review of scientific papers based on search keys, 
from the year of 2000 to 2014, including full texts and abstracts.  
There was different criteria for selecting studies due to inclusion criteria (Walker 
et al., 2008). The criteria listed was as follows: 
• There should be enough information for analysis, such as point estimate 
and standard deviation  
• The study design should be the same 
• The year of study and collected data should be related to the target 




• The minimum sample size must be met 
• The age of the study group must be appropriate 
I excluded studies on different genes than the selected one-carbon metabolism gene 
polymorphisms in this study. The other exclusion criteria included independent studies or 
statistical methods and study designs that were different from the goal of this study. 
Inclusion and Exclusion Criteria 
The eligibility criteria for the studies were the following:  
• All collected data were from males 
• All types of publications 
• All published articles in all languages 
• Studies with a case control and cohort design 
• Studies with results of odds ratios, related risks, and p-values  
• Reliable measures  
The study collection was limited to a publication date of 2000 or after.  
In this study, I planned to limit the research on the human genome,and SNP 
analysis on the human population. Some studies were excluded if they included an 
analysis of several genes and did not include the selected one-carbon metabolism gene 
polymorphisms (MTHFR, MTR, and MTRR). I also excluded research where the 






Researchers have examined the association between one-carbon metabolism gene 
polymorphisms and prostate cancer with differing results. Not only is prostate cancer a 
health concern for many males, the health costs associated with treating this cancer are 
also significant. The cost of treating prostate cancer for diagnosis and follow-up 
treatment in the United States in 2006 was 9.862 billion (Roehrborn & Black, 2011), and 
the cost of treatment in Canada was 9.76 billion dollars (Fradet, Klotz, Trachtenberg, & 
Zlotta, 2009). Prostate cancer affects all social, physical, and psychological aspects of a 
patient’s life.  
Epidemiology of Prostate 
Prostate cancer is the most common diagnosed cancer among Canadian males. 
According to statistics, 23,600 Canadian males will be diagnosed with prostate cancer, of 
which 3,900 of them will die from the disease (“About Prostate Cancer - Prostate Cancer 
Canada,” n.d.). One in 7 males will develop prostate cancer during their lifetime; the rate 
for death from prostate cancer is 1 in 27 or 1 of 4 diagnosed males (Fradet et al., 2009). 
Fradet et al. (2009) claimed that the diagnosing and mortality from the disease of prostate 
cancer occurs as often in males as breast cancer occurs among females. However, the 
death rate from prostate cancer decreased significantly (almost 4%) from 2001 to 2009 
due to improved testing procedures for prostate cancer and more efficient treatment 
strategies to reduce the risk. 
The prostate is a male organ. The prostate organ is located below the bladder, in 




prostate is the male reproductive organ that adds nutrients and fluid to the sperm. 






Figure 3. The anatomy of the prostate organ in the human body, male. From “About 
Prostate Cancer - Prostate Cancer Canada,” n.d. .  
 
The incidence rate and mortality of prostate cancer with adjusted age-standardized 











Dorr et al. (2013) indicated that prostate cancer is the second most diagnosed 
cancer in males after lung cancer. Dorr et al. pointed out that the highest incidence rates 
of prostate cancer occur in Australia and New Zealand. The lowest incidence rate for 
prostate cancer is in South-Central Asia. Dorr et al. showed that the highest mortality rate 
for prostate cancer occurs in the South African Republic. Almost three quarters of these 
diagnosed males are from developing countries. 
Grönberg (2003) explained the differences between ethnic populations and 
diagnosis of prostate cancer as related to their genetic background and the environment 
effects. Grönberg found that, when Japanese people moved from Japan to the United 
States, the incidence rate of prostate cancer increased among the males in this population. 
The increase in prostate cancer was associated with adoption of the Western lifestyle, 
including dietary intake and habits. Specifically, Grönberg indicated that there was a 
relationship between dietary factors and prostate cancer risk. The dietary factors related 
to prostate cancer include a large consumption of red meat, as well as the way of cooking 
and preparing such as high temperature cooking that may cause diseases such as 
colorectal, bladder, and kidney cancer. Phyto-estrogens, in soybean products, is also 
linked to reducing prostate cancer (Grönberg, 2003). Grönberg explained that frequent 
intake of tomato-based products might cause a reduction in prostate cancer because of 
lycopene. 
The Economic Burden of Prostate Cancer 
There are many costs associated with prostate cancer, specifically in diagnosis 




prostate cancer is evaluated in five phases per 100 days (2004, $Canadian): (a) before 
diagnosis (6 months before, Phase I) $1,297, (b) initial care (12 months after diagnosis, 
Phase II) $3,289, (c) continuing care (Phase III) $1,495, (d) preterminal care (from 18 to 
6 months before death, Phase IV) $5,629, and(e) terminal care (6 months before death, 
Phase V) $16,020 (Krahn et al., 2010).  
Risk Factors 
There are many risk factors related to prostate cancer. In the United States, age is 
a factor relating to prostate cancer; more than 70% of all cases of prostate cancer are 
diagnosed in males aged over 65-years-old (Crawford, 2003). Crawford (2003) added 
that there is some evidence of diagnoses of prostate cancer among males age less than 50-
years-old. Ethnicity, another risk factor, is related to the diagnosis of prostate cancer as 
African Americans have the highest rate of the disease in the world. Crawford indicated 
that males who have a family history of the prostate cancer are also at an increased risk of 
prostate cancer. The androgen hormone level in the blood is related to the incidence of 
prostate cancer. Males with a high body mass index (BMI) of 35 to 39.9 have a 34% 
greater risk of dying of prostate cancer than those with a lower BMI (Crawford, 2003). 
Smoking may correlate to prostate cancer tumor growth, although the direct effect is not 
evident (Grönberg, 2003). Chemical exposure to pesticides and herbicides may affect a 
male’s likelihood of developing prostate cancer (Fradet et al., 2009). Fradet (2009) 
indicated that Selenium and Vitamin E might affect prostate cancer risk.  
One-Carbon Metabolism Gene Polymorphisms 




role in processing amino acids for building proteins. The genomic DNA is at the root 
cause of certain diseases, including prostate cancer, by mutating the genes and their 
protein structure. Some materials involved in one-carbon metabolism, due to DNA 
synthesis and methylation modification, are Vitamin B families, in particular folate or 
Vitamin B9 (Donkena, Yuan, & Young, 2010). There are different genes involved in one-
carbon metabolism reaction. I studied three one-carbon metabolism genes: MTHR, MTR, 
and MTRR. The other genes involved in the one-carbon metabolism reaction are CBS, 
FOLR1, TYMS, BHMT, SHMT, SLC19A1, GGH, and ALDH1L1. 
MTHFR (C667T, A1298C) 
The function of the MTHFR gene is to produce the methylenetetrahydrofolate 
reductase enzyme (NCBI, 2014). This enzyme is important to the reaction of Vitamin B 
folate, folate metabolism (Figure 6). This enzyme transforms the amino acid 
homocysteine to amino acid methionine (NCBI, 2014). Without functional MTHFR, the 
body will not transform homocysteine to methionine, which leads to a reduction of 
methionine amount. Wojcieszynska et al. (2012) believed 
The concentration of homocysteine in plasma is associated with several metabolic 
disorders such as; triglyceride level in plasma, body mass index (BMI), 
hypertension, and abnormal oxidation of low-density lipoprotein, which may lead 
to the development of a wide variety of cancers, such as breast, ovarian, and 
pancreatic cancers. (p.16755) 
There were two polymorphisms of the MTHFR gene analyzed in this study: 




677 (677C>T, rs1801133)  at Chromosome 1 location p36.3, Exon 4 in humans genome 
(Figure 5) leads to the substitution of alanine amino acid to valine amino acid, which may 
cause reduced activity of the enzyme (Wojcieszynska et al., 2012). The wild type of this 
gene is nucleotides C, and the mutated gene in MTHFR may choose to turn off the 
enzyme activity by changing to Nucleotides T. The second most frequently occurring 
polymorphism is changing nucleotide adenine to cytosine (1298A>C, rs1801131) at Exon 
7, Chromosome 1 Location p36. 3 (see Figure 5).  
 
 
Figure 5. The location of MTHFR gene on the short arm (p) of chromosome 1 at position 
36.3. The MTHFR gene is located from base pair 11,845,786 to base pair 11,866,159 on 
chromosome 1 (Source: NCBI, 2014). 
 
The wild allele is A, against mutate one T. This transforming nucleotide results in 
the changing of glutamate amino acid to alanine amino acid at Codon 429 (NCBI, 2014). 
Those two folate and riboflavin protect against the loss of function of MTHFR, which 
can reduce the risk of cancer (Figure 6). 
MTR (A2756G) 




(Figure 6). This gene interacts at an enzyme called methionine synthase (NCBI, 2014). 
This gene affects the synthesis of amino acid methionine from converting amino acid to 
homocysteine (Figure 7). 
 
 
Figure 6. The relation between MTHFR genotype, riboflavin, and folic acid with respect 
to (a) cytosine-phosphate-guanosine dinucleotide (CpG) methylation and uracil in DNA 
and (b) initiation of cancer caused by CpG hypomethylation. The level of riboflavin and 




The transformation of adenine to guanine is a mutation of this gene at 2756 
position (2756 A>G, rs1805087). A few scholars have examined MTR and prostate 
cancer risk (Watkins et al., 2002; Yu et al., 2010). The wild and normal version of allele 
at base pair is A, which is the mutated version of G. The mutation in the MTR gene 
causes the production of an unusually small, nonfunctional version of methionine 






Figure 7. Folate metabolism. BHMT = Betaine-homocysteine methyltransferase; B6 = 
vitamin B6; B12 = vitamin B12; CβS = Cystathionine β- synthase; CH3 = Methyl; dATP = 
Deoxyadenosine 5’-triphosphate; dGTP = Deoxyguanosine 5’-triphosphate; dTTP = 
Deoxythymidine 5’-triphosphate; DHF = Dihydrofolate; DHFR = Dihydrofolate 
reductase; Hcy = Homocysteine; MTHFD1 = Methylenetetrahydrofolate dehydrogenase 
1; MTHFR = Methylenetetrahydrofolate reductase; MTR = Methionine synthase; MTRR 
= Methionine synthase reductase; RFC1 = Reduced folate carrier 1; SAH = S-
adenosylhomocysteine; SAM = S- adenosylmethionine; cSHMT= Serine 
hydroxymethyltransferase; TC2 = Transcobalamin 2; THF = Tetrahydrofolate (source; 




The MTR gene is located from base pair 236,958,580 to base pair 237,067,280 on 
Chromosome 1 (see Figure 8). 
 
Figure 8. The MTR gene is located on the long arm (q) of chromosome 1 at position 43. 
(Source: NCBI, 2014). 
 
MTRR (A66G) 
The MTRR instructs an enzyme to methionine synthase reductase name. This 
enzyme helps to process amino acids used to build proteins, which the MTRR enzyme 
causes to produce an active or inactive methionine synthases (Watkins et al., 2002). The 
wild version of allele in this gene is A, and the mutated version is G, which may happen 
at Position 66 of the MTRR gene (66A>G). The mutated version may cause 
abnormalities and a nonfunctional version of the enzyme, which changes the single 
amino acids in the process of methionine synthase reduction (Rai, Yadav, Kumar, & 
Yadav, 2013). This prevents functionality of the enzyme, which may lead to a reduction 
for (the amount) methionine associated with homocystinurin process (Figure 7). The job 
of the MTRR is to activate or inactivate MTR (Rai et al., 2013). This gene is in the short 
arm (p) of Chromosome 5, at Position 15.31 (rs1801394, base pairs 7,851,298 to 





Figure 9. The MTRR gene is located on the short arm (p) of Chromosome 5, at Position 
15.31. The MTRR gene is located from base pair 7,851,298 to base pair 7,901,236 on 
Chromosome 5 (Source: NCBI, 2014). 
 
Gene Interactions 
Public health workers lead health care policy and disease prevention. Genetic 
study is involved in the study of gene and environment interaction. The ancestry and 
ethnicity of people play a role in the location of genes in their genomic model (Feero, 
Guttmacher, & Collins, 2010). Feero et al. (2012) indicated that the difference in gene 
location in different people leads to specific gene variations. The definition of a normal 
or wild gene refers to the most common variant of a specific gene location in a given 
population group. These genetic variations affect human health. The normal frequency 
for a minor allele is 99.9%, and if there is more than a 1% variant in the same population 
group, it is called a polymorphism (Feero et al., 2010). 
Gene-Environment Interaction 
The association between common diseases and environmental factors such as diet 
and lifestyle also relate to genes. The interaction between genes and the environment 




environment is in the etiology of most diseases (Feero et al., 2010). The genotype affects 
the phenotype; with gene mapping (DNA analysis), the phenotype of the diseases can be 
seen. In epidemiological methods and analysis, researchers analyze environmental 
exposure and lifestyle and how it relates to disease (Hunter, 2005). Rhee and Waldman 
(2002) explained the etiology of antisocial behavior as a combination of genetic and 
environmental influences. There is a significant association (P=0.04) as reported by 
Lindstrom et al. (2011) on gene –environment interaction between diabetes and 
JAZF1gene in addition to a significant association (P=0.03) between JAZF1 and BMI. 
Kobayashi et al. (2012) indicated the effect of nutrient intake, Vitamin B groups, and 
folate intake to prostate cancer risk.  
Gene-Gene Interaction 
In genetic study, scholars look at the association between genotype and phenotype 
at the individual level. The gene-gene association includes looking at different loci (gene) 
association in the chromosome, which is measured by a linkage disequilibrium value 
(Cordell, 2009). The linkage disequilibrium is a nonrandom association between two or 
more loci in the chromosome (Cordell, 2009). Yeager et al. (2009) showed a gene-gene 
association of prostate cancer on Chromosome 8 (q-arm). There is an association between 
rs62086 and rs13281615 with linkage disequilibrium (LD) of 0.38 (r2=0.30), which is a 
modest LD (Yeager et al., 2009). 
Diet Including Folate Intake, and Prostate Cancer 
Mazhar and Waxman (2004) and Shirai et al. (2002) suggested that the incidence 




from Asia to the United States. Diet as a risk factor for prostate cancer includes the intake 
of food rich in fat and as well as the consumption of red meat. To prevent prostate cancer, 
a male should consume soy protein and nutritional supplements such as Vitamin E, 
selenium, zinc, isoflavones, and lycopenes (Mazhar & Waxman, 2004). According to 
Shannon et al. (2009), folate is a micronutrient that involves metabolism; one-carbon 
metabolism is associated with changes in the methylation status of genes that involve 
carcinogenesis. Although there is not a strong association between folate intake and 
prostate cancer, Pelucchi et al. (2005) showed this association in an Italian population. 
More study on this interaction needs to be done. 
Cancer Genetics 
Cancer genetics includes studying genes that relate to cancers. The genes 
controlling the cell maintain the function of the cell. In cancer, the genes show a mutation 
that causes abnormalities in cellular activities, such as an uncontrolled growth 
(oncogenes), which may cause tumors like BRCA1 and BRCA2 that cause breast cancer 
(Ponder, 2001). Cancer is caused by mutation in DNA (deoxyribonucleic acid) segments, 
which leads to abnormal growth in a cell. The genotype will map mutated genes, which 
can be inherited and transferred from parents to the offspring; in epidemiology, a gene by 
environmental influence causes an individual’s phenotype (Feero & Guttmacher, 2010). 
A small portion of cancers can be inherited (Ponder, 2001). Prostate cancer occurs due to 
metastatic disease; there are some environmental risk factors that affect the incidence of 
this disease (Dean & Lou, 2013). Dean et al. (2013) concluded that there is a high risk of 




Sweden, males with a family history of PC is 3 to 10 folds higher than regular males in 
the same community group. 
Theoretical Foundation 
In health and health behavior research, the theories and models help scholars to 
understand the concepts of the study and design interventions through its approaches. 
Theories and models are used to answer the health problems and find the effective ways 
to change a person’s behavior (Coreil, 2010). In this study, the outcomes were based on 
genetic epidemiology at multilevel models of health behavior,w hich could be used to 
help change health behavior in individuals. The gene-prostate cancer association, if 
found, could help facilitate genetic screening to diagnose the disease at the early stage of 
prostate cancer. At the individual level, the men who partake in prostate cancer screening 
could detect the disease at an early stage, which would benefit him with an early 
treatment strategy to increase his life expectancy. The early diagnosis of prostate cancer 
could effect to the treatment cost (less cost for patients) and effective treatment strategies. 
At the community level, the prostate cancer genetic screening could help community 
members to understand the health conditions that lead to prostate cancer and plan 
programs at different private and public health sectors to alleviate these conditions 
(Coreil, 2010). 
One-Carbon Metabolism Gene Polymorphisms and Prostate Cancer Risk 
In genetic association studies, researchers test the relationship between genetic 
variations and health outcomes; health outcomes are mainly diseases. In recent studies, 




2011). Khoury (2011) believed that public health authorities are responsible for 
coordinating health care and disease prevention, which involves the examination of 
human genomes to improve preventative health measures. Genomic information not only 
helps to improve population health, but also can be used to develop health protection 
strategies for the future (Khoury et al., 2011). A genetic test would improve the detection 
of genetic diseases at an early stage. 
The studies on genetic-prostate cancer association help to identify gene effect to 
the risk of prostate cancer due to an individual’s genotype. The genetic polymorphisms 
frequencies present differentially among men in different regions and ethnic groups. 
There is an association between genetic polymorphisms among diverse populations and 
risk of prostate cancer (Li, Mercer, Gou, & Lu, 2013). Males who immigrate from Asia to 
The United States respond to genetic polymorphisms related to the incidence rate of 
prostate cancer, and have a higher risk of prostate cancer (Grönberg, 2003; Li et al., 
2013). The highest incidence rate of prostate cancer is among African men, with 
intermediate rates among Caucasian men, and the lowest rates among Asian men (Ntais, 
Polycarpou, & Tsatsoulis, 2003). In this this meta-analysis study, I examined the 
association between ethnic groups and risk of prostate cancer due to mutated genes on 
MTHFR, MTR, and MTRR genetic polymorphisms.  
The association between one-carbon metabolism gene polymorphisms and 
cancers are reported in different articles (Gibson et al., 2011; Theodoratou et al., 2012; 
Xu et al., 2008). In this meta-analysis, I combined the results of 20 selected studies on the 




risk. The 20 selected studies were from 2800 studies review (Figure 10). Researchers 
have reported differing relationships between this association, but the studies have a 
variety of regions and ethnicity of participants studied. The results may be used to better 
understand how the association for each group could relate to common ancestry, 
environmental risk factors, and genotype. The gene-environment interaction is an 

















Figure 10. The flow diagram of study selection process. 
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In this study, I reviewed 20 articles with similar boundaries. In this study, I 
provided a better understanding of the results because of the increased sample size in the 
analysis, which increases the power of the test. Although a meta-analysis would improve 
the power of the test, there may are some missing technical performance that can make 
the study more accurate; this is the advantage of research. This meta-analysis involved 20 
primary studies on the association between one-carbon metabolism gene polymorphisms 
and prostate cancer. In this study, three genes MTHFR, MTR, and MTRR were 
identified. An abstract on the 20 included studies is located in Appendix A. 
Kimura et al. (2000) conducted a hospital-based case control study and reported a 
slight association between MTHFR and prostate carcinoma, but this association was not 
statistically significant at the 5% level of the test. Kimura et al. sampled participants from 
a German population (Caucasian); there were 132 prostate carcinoma patients, 66 of 
whom were involved in this study and 150 participants who were PC free as a control 
group. Although Kimura et al. found no significant association between MTHFR and 
prostate cancer; there was an association between MTHFR Val allele (T) and higher 
tumor grade. Kimura et al. suggested further study with a higher sample size. The results 
of the genotype and allele frequencies were used for this meta-analysis study. 
Heijmans et al. (2003) reported different results than those of Kimura et al. 
(2000). Heijmans et al. suggested that at Polymorphism C677T, Genotype CC is a risk 
factor for cancer in elderly males. In a cohort study design, Heijmans et al. examined 149 
new cases of cancer among 793 males without cancer. The population of the study was 




cancer among males who consumed large amounts of alcohol and those with less folate 
intake.  
Cicek et al. (2004) found a slight association between prostate cancer and 
A1298C. There was a positive association between the C677T variant and prostate cancer 
risk among males who had a less advanced disease. In this case-control study, there were 
with 439 cases and 479 sibling controls. The study was a population-based study among 
Caucasian ethnic groups. The sample study was from sibling groups. The brothers with 
cancer were aged less than 73 years, and the control group included brothers who were 
<8 years younger than the older brother diagnosed with the disease. Van Guelpen et al. 
(2006) found different results than Cicek et al. Van Guelpen et al.  showed that there was 
no significant association between prostate cancer and C677T polymorphism. Van 
Guelpen et al.'s population included Swedish males.  
Singal et al. (2004) showed a significant association between polymorphisms 
(C677T, A1298C) and the reduction of the risk of developing prostate cancer. The study 
was a case-control study with 81 patients and 42 controls, including Caucasians and 
African American ethnic groups, in the United States. There was a significant association 
between polymorphism C677T and risk of prostate cancer among males under 65 years 
of age in Johansson et al.’s (2007) study, but, overall, Johansson et al. found no 
significant association. Johansson et al.’s study was a case-control, population-based 
study of Swedish people. 
Reljic et al. (2007) studied MTHFR polymorphisms and cancer risks. Reljic et al. 




control study. This study was a population-based study that resulted in no significant 
association between the C677T polymorphism and prostate cancer. Marchal et al. (2008) 
indicated a significant association between MTHFR C677T and prostatic carcinogenesis 
among Caucasian people in Spain. Marchal et al.’s study was a hospital-based, case-
control study with 182 cases and 205 controls.  
Stevens et al. (2008) showed no association between one-carbon, metabolism 
gene polymorphisms (MTHFR, MTR, MTRR) and prostate cancer risk. The study was a 
population based case-control study. Stevens et al. studied the association between nine 
one-carbon, metabolism genes and the risk of prostate cancer in 1,144 cases and 1,144 
controls. Muslumanoglu et al. (2009) studied the Turkish population (Caucasian) in a 
hospital-based case-control study. The study involved 93 prostate cancer patients and 166 
individuals in the control group; participants were aged between 5- to 89-years-old. 
Muslumanoglu et al. did not find a significant difference of T allele frequency between 
patients and control groups on A677T polymorphism, but there was a difference in C 
allele frequency of A1298C polymorphisms between patients and control groups. 
Cai et al. (2010) pointed to a significant association in genotypes and alleles 
between cases and controls for C677T polymorphisms, but there was not any association 
for C677T polymorphism and MTR and MTRR genes with prostate cancer. The study 
was a hospital-based case-control study involving 217 cases and 220 benign prostatic 
hyperplasia (BPH) controls. Safarinejad et al. (2010) believed that there was an inverse 




was from an Iranian population (Caucasian) as a population-based case-control study. 
The study involved dietary Vitamin B12 and folate intake.  
Wu et al. (2010) conducted a Taiwanian, hospital-based case-control study on 218 
cases and 436 controls. Wu et al. showed that C677T polymorphism had a significant 
association with the decrease in the risk of prostate cancer, but there were no frequency 
differences between patients and controls for A1298C polymorphism. Wu et al. provided 
the first evidence of an association on C allele frequency of C677T polymorphism and 
developing prostate cancer. Küçükhüseyin et al. (2011) found no significant association 
between the C677T polymorphism and prostate cancer risk, even though there was a 
decreased risk of prostate cancer. The study was a hospital-based case-control study of 
Turkish people. There were 55 cases and 50 healthy controls involve to this study. 
Fard-Esfahani et al. (2012) studied an Iranian population and found no association 
between the C677T polymorphism and the risk of prostatic carcinoma. The study 
involved a hospital-based case-control study with 67 cases and 75 controls. There was a 
slight effect of homozygote (TT vs. CC) on the carcinogenesis. Jackson et al. (2013) 
indicated no association between MTHFR, MTR, and MTRR genes and prostate cancer. 
Jackson et al. reported a gene- prostate cancer association for those male with high folate 
concentrations. The study involved a population-based case-control study among males 
aged 40-80 years old.  
 López-Cortés et al. (2013) found an association between C677T polymorphism 
and the risk of prostate cancer, plus a slight association between A66G polymorphism 




individuals. The study involved 104 cases and 110 participants in a healthy control group; 
the participants were of Spanish ethnicity. Kobayashi et al. (2012) showed a significant 
association between alcohol consumption and folate intake related to prostate cancer by 
C677T variants. The study was a hospital-based case-control study with 80 cases and 334 
controls. There was no association between the C677T variant and prostate cancer. This 
study was on gene-environment interactions subject.  
 De Vogel et al. (2014) indicated that, in the gene-environment interaction, there 
was an interaction between MTHFR C677T polymorphism and Serum sarcosine and 
glycine concentrations. De Vogel et al. showed that high glycine concentration or serum 
sarcosine had a moderate effect on reducing prostate cancer risk. De Vogel et al. found a 
significant association between variant TT relation to prostate cancer (p-value=0.004). 
The study was a population-based nested case-control study with 2,522 cases and 2,607 
controls. Ebrahimi et al. (2013) found that there was no significant association between 
the C677T variant and prostate cancer risk. It was a hospital-based case-control study 
with 30 cases and 40 controls. Ebrahimi et al. also studied prothrombin (PTH, G20210A), 
and Venous thromboembolism (VTE, G1691A) genes, in which Ebrahimi et al. could not 
find a significant association.  
 Limitations of these studies were in sample size; some of the studies had a small 
sample size. The age group was another limitation; some studies involved a varied group 
of males (ages 40-85); the studies should have included younger people who are at risk of 
prostate cancer. The other limitation was dietary intake; some studies involved folate and 




regions and different ethnic groups, in the final meta-analysis, this disparity may affect 
the analysis of differences between regional groups. 
Review of Relevant Methodology, Meta-Analysis 
This study’s methodology was based on a multiple study analysis or meta-
analysis. A meta-analysis is a study that combines the results from different studies to 
identify the common patterns among studies. The main goal of a meta-analysis is to 
develop the power of the test by increasing the sample size. The other objectives of a 
meta-analysis are to analyze the differences among the studies’ results, to evaluate the 
effect of subsets in disease exposure, and to determine the gap for future studies (Walker 
et al., 2008).   
The advantages of meta-analysis are 
• To improve the power of test to estimate the effect size 
• Generalize the results of study in the wider area 
• To estimate the variation between studies (heterogeneity) 
• To evaluate the publication bias 
The disadvantages of meta-analysis are 
• The way that data are collected at each study and the process of inclusion 
and exclusion 
• The statistical analysis and adjustments for cofactors in individual studies 
• The publication bias 




• The selection bias 
• A lack of uniformity of outcome measurement 
In a meta-analysis, there are different models used to conduct statistical analysis: 
fixed effects, random effects, heterogeneity of results, and sensitivity analysis. In 
addition, a funnel plot and forest plot are used. In the fixed effects model, the treatment 
effect assumes the same in all of the studies, and the analysis will estimate this unknown 
effect, which would be more precise than in an individual study. In the random effect 
model, the treatment effect is not the same across studies, and a meta-analysis researcher 
estimates the average effect of the studies. The random effect model has larger variances 
and confidence interval compared to a fixed effect model. The heterogeneity analysis will 
be used to show the variation among the studies. The heterogeneity analysis determines 
homogeneity of effect size in all of the studies, which involves the meta-analysis. I was 
interested in finding the differences among studies by heterogeneity analysis. If there was 
a high value of heterogeneous, greater than 0.55, I conducted a meta-regression analysis. 
The meta-regression analysis may be used to show the cause of variation among study 
variability (Bartolucci & Hillegass, 2010). 
The sensitivity analysis was used to determine the strength of the findings and to 
show how the results may differ if there is more inclusion or exclusion studies in the 
meta-analysis. The sensitivity analysis in a meta-analysis involves an investigation with 
a high number of studies. A funnel plot is used to show the biases in the meta-analysis. 
The funnel plot has a funnel symmetric shape with an average effect size in the center of 




forest plot is a summary of individual studies’ point estimate, which is bounded by its 
confidence interval including an overall effect. The forest plot is used to display the 
information easily (Borenstein et al., 2009).  
Summary 
In this chapter, I explained the literature related to one-carbon metabolism gene 
polymorphisms association and prostate cancer risk (Appendix A). The included genes 
were MTHFR gene with two polymorphisms C677T and A1298C, the MTR gene with 
A2756G polymorphism, and MTRR gene with A66G polymorphism. In this chapter, I 
discussed the prostate cancer epidemiology and its relation to public health care and the 
economic burden of prostate cancer regarding the diagnosis and death. The search 
strategy, including inclusion and exclusion criteria, were described in this chapter. 
The number of included eligible studies for MTHFR gene C667T polymorphism 
was 20 studies with 8,675 cases and 9,207 control participants in each group. The total 
number of eligible studies for A1298C polymorphism was 11 studies with the total 
number of 2,922 cases and 3,644 controls. The gene of MTR, A2756G polymorphism, 
had four eligible studies included this meta-analysis with the total number of 701 cases 
and 739 controls included in the analysis. The MTRR gene, A66G polymorphism, 
included four eligible studies with the total number of 698 cases and 737 control 
participants. 
This study covered the gap of gene-prostate cancer associated with a higher power 
of test than previous studies by conducting a meta-analysis study. The risk factors, 




chapter. I explained the morphology and selected gene’s cytogenetic location. I explained 
how these genes would influence folate balance. The gene-gene and gene-environment 
interaction is a subject for future research. Policy-makers must develop policies to 
diagnose prostate cancer at an early stage to reduce the development of the disease. In 




Chapter 3: Research Method 
Introduction 
The aim of this meta-analysis study was to increase the power of the test for gene 
disease association. In this study, I planned to conduct an analysis of the association 
between one-carbon metabolism gene polymorphisms and prostate cancer risk. One-
carbon metabolism gene polymorphisms are the genes related to diseases, such as breast 
cancer, colorectal cancer, and lung cancer (Suzuki et al., 2008; Suzuki et al., 2007; 
Theodoratou et al., 2012). In this study, I combined the results of each selected study 
(effect size) with a common concept to estimate the combined effect size with a more 
accurate estimation than in an individual study. In a meta-analysis, each study will bring 
an effect size with a defined sample size to the analysis. With an increased power of the 
test, a more accurate result of the association will be provided. Each individual study has 
a method to calculate the odds ratio (effect size), including different independent 
variables, such as age, family history, ethnic groups, region, and folate consumption. The 
meta-analysis research design is based on the association between the dependent and 
independent variables common to each study. The published articles had to meet 
inclusion criteria to be involved in this study; the data collection was based on study 
subject and common concepts.  
In this chapter, I describe the analysis of the data in different processes: fixed 
effect model, random effects model, and heterogeneity. I used a funnel plot and forest 
plot to show a summary of the individual studies’ point of estimate and their boundaries, 




Research Design and Rationale 
Each included individual study of this meta-analysis had its own study design, but 
all of the studies included in this meta-analysis looked at the association between one-
carbon, metabolism gene polymorphisms as independent variables and prostate cancer as 
a dependent variable. Each study had its own statistical methods to estimate the effect 
size, but the most common results were an odds ratio (Szumilas, 2010). The odds ratio is 
the ratio of two odds, odds=probability (D: disease) /probability (H: no disease), which 
show the probability of the disease in the target population. The study had the following 






Genotype Association with Cases (D: Disease) and Controls (H: Healthy) 
Genotype  Cases Controls Case: Control Ratio 
    
A/A DA/A HA/A DA/A/HA/A 
A/a DA/a HA/a DA/a/HA/a 
a/a  Da/a Ha/a Da/a/Ha/a 
 
The estimation of odds with a/a as a reference are 
    , and    
 The calculation of confidence interval (CI), usually at 95% level, was based on 
the value of OR. The CI is the width used to estimate the precision of OR; the larger 
value of CI shows a low level of precision of OR, and a lower value of OR indicates a 
higher precision of the calculated OR. The formula for calculating the CI is exponentiated 
endpoints of  
 ln (OR) (SD) 
Research Questions and Hypothesis 
 The genes and disease association were reported from many studies, including 
gene-cancer association (Taylor, Najafi, & Dobson, 2007; Theodoratou et al., 2012; Xu et 




prostate cancer. The purpose of this study was to examine the relationship of prostate 
cancer risk and one-carbon metabolism gene polymorphisms. Although other researchers 
have analyzed this association, there were different findings: some scholars reported a 
positive association; some reported that there was no association, and some asked for an 
increased sample size to make an accurate study result. The purpose of this meta-analysis 
was to estimate the overall effect size by increasing the statistical power of the test, 
compared to a primary study, based on an increase the sample size of the test. In this 
meta-analysis, I combined multiple studies to achieve a quantitative estimation of the 
overall effect size at alpha (0.05) level of the test.  
Research Questions 
The research question regarded the examination of the relationship between one-
carbon metabolism gene polymorphisms and prostate cancer risk.  
1. Is there any significant association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk? 
H1o: There is no association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
H1A: There is an association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
2. Are there any significant differences between regions of the globe due to 
gene-disease association? 
H2o: There are no differences between regions due to gene-disease association. 




3. Are there any significant differences between ethnic groups due to gene-
disease association? 
H3o: There are no differences between ethnic groups due to gene-disease 
association. 
H3A: There is a difference between ethnic groups due to gene-disease association. 
The region in this study was the independent variable to determine its association 
with prostate cancer risk. People in different regions have different ancestry, which is 
important in a population genetics study. The ancestry carries a set of genes, which are 
common for those groups of the people. Those specific genotypes in the group make a 
different phenotype for them, which may affect their lifestyle and risk factors for prostate 
cancer such as nutrient intake and healthy activity. The regions in this study were in three 
groups of continents: the Americas, Europe, and Asia. Those studies in the Americas 
continent were added as the American region, those countries in Europe counted as the 
Europe anregion, and those countries in Asia were count as Asian region. In this study, I 
included research on four different ethnic groups: Caucasians, African American, Asian, 
and Spanish. I adjusted for those covariates at the first level of study.   
Methodology 
The target population was those men who were at risk of prostate cancer.    
Data Collection 
 The data collected from selected studies were based on inclusion and exclusion 
criteria. I found over 2,800 studies involving genetic association with cancers. I narrowed 




polymorphisms (MTHFR, MTR, MTRR) and prostate cancer risk. All of these selected 
studies used the same statistical model to determine the effect sizes (odds ratios); only 
one of the studies had calculated the effect size as related risk. In the case of rare 
diseases, the odds ratio value was close to relative risk value (Borenstein et al., 2009). 
The data collection included the data available from the 20 selected individual studies, 
which allowed me to calculate the size effect value (OR) and its confidence interval value 
of the combined data. 
Dominant Model 
 The gene has two alleles; in the dominant model, one allele trumps the other allele 
(Lewis & Knight, 2012). The dominant model in the gene MTHFR, polymorphism 
C677T, is (CT+TT) vs. CC. (CC, reference), and in the polymorphism A1298C, it is (AC 
+CC) vs. AA (AA, reference). The dominant model in the gene MTR, polymorphism 
A2756G is ((AG +GG) vs. AA (AA, reference), and in the gene MTRR, polymorphism 
A66G, it is ((AG +GG) vs. AA (AA, reference).  
Codominant Model 
 The codominant model in the gene MTHFR, polymorphism C677T, is TT vs. CC 
or CT vs. CC (CC, reference) and, in the polymorphism A1298C, it is CC vs. AA or AC 
vs. AA (AA reference). The codominant model in the gene MTR, polymorphism 
A2756G, is GG vs. AA or AG vs. AA (AA, reference) and, in the gene MTRR, 





 The recessive model in the gene MTHFR, polymorphism C677T, is TT vs. 
(CT+CC; CT+CC, reference) and, in the polymorphism A1298C, it is CC vs. (AC+AA; 
AC+AA, reference). The recessive model in the gene MTR, polymorphism A2756G, is 
GG vs. (AG +AA; AG+AA, reference) and, in the gene MTRR, polymorphism A66G, it 
is GG vs. (AG +AA; AG+AA, reference). 
 In some articles, the allele count was not included; I calculated it based on the 
genotype. The formula for allele count was 
Allele A= 2 [AA+ (AB/2)] 
AA was when both alleles in a genotype were the same; AB was while one of 
those two alleles that was counted. 
Data Analysis 
In a meta-analysis, the researcher is looking for two variations in outcome: 
within-study variation and between-study variation. The within-study variation is due to 
the individual of number of cases and the response to the treatment (genes) effect. The 
between-study variation is due to the mean of the outcome in study-to-study (Laird & 
Mosteller, 1990). The variation estimation is important because of its role to the weight 
of the study (Borenstein et al., 2009). The weighting strategy was based on the method 
inverse of variance ( =  ), in which the variance is based on combined, within, and 




In the fixed-effect analysis, I used the within-study variance in weight of the study 
(weight=1/within-study variance) and, in the random-effects analysis, I used both 
variances to weight the study (weight=1/within plus between-study variances). 
In this study, the effect size for each individual study was OR, which was the ratio 
of cases in the control group. With the combination of the size effects (overall OR), the 
statistical method included log ORs: 
LogOddsRatio= Ln (Odds Ratio) 
The confidence interval for lower and upper limits respectively was 
LLOddsRatio= exp(LLLogOddsRatio), ULOddsRatio= exp(ULLogOddsRatio) 
The formula of converting relative risk to odds ratio is (Zhang & Yu, 1998):  
OR =  
In the case of rare diseases, the odds are valued the same as related risk 
(Borenstein et al., 2009; Zhang & Yu, 1998). The statistical analysis software for this 
study was Statistical Analysis System (SAS 9.3).  
Heterogeneity 
 In the heterogeneity analysis, the null hypothesis was no heterogeneity, which 
means the genes have the same effect of prostate cancer risk in all studies (k=20). The 
alternative hypothesis is the gene's effects varied over studies included in the meta-
analysis. 




 Ha: There is variation between studies regarding gene-prostate cancer association 
I used this test to estimate the consistency among the effect size across the 
included studies in the meta-analysis. If I rejected the null hypothesis, it means that there 
was heterogeneity among studies. To test the heterogeneity among studies, I used a 
formal test called Q statistics (quantifying heterogeneity). In the estimation of a Q-
statistic, if the value is close to 0, it means there is no heterogeneity. If each study has an 
effect size close to the mean effect size, there are no differences in effect size. The Q-
statistics has a chi-square distribution with all studies minus one degree of freedom (K-1= 
df).  
H0: Q=0  
Ha: Q≠0 
The computation formula to estimate heterogeneity is (Borenstein et al., 2009) 
 
Where Wi is the study weight calculated by the inverse of a variance, Yi is the 
study effect size (OR), and k is the study numbers. 
The I2 index explained the extent of heterogeneity across studies by comparison to 
the expected value. The value of I2 has a value of 0% to 100%, which was used to 
interpret the percentage of heterogeneity across studies (variances between studies). It is 




to 0, it means the variation in effect size is due to sampling error within studies 
(Borenstein et al., 2009); 
I2 =   100% 
The value of I2 by Higgins, Thompson, Deeks, and Altman (2003) is considered 
to be equal to 25%, 50%, and 75%, which is called small, moderate, and large degrees of 
heterogeneity among effect sizes. 
Meta-Regression 
If I found a Q statistic with a large value of I2 (>0.55), I used a meta-regression to 
find the cause of variability among study. The dependent variable in this meta-regression 
was the OR from individual studies. I assumed that those covariates had a major cause of 
heterogeneity. The assumption in a meta-regression is due to the variables. In a meta-
regression, all interested variables are available in all studies as the source of 
heterogeneity. These variables include the meta-regression analysis. As an example, age 
may be a variable in one study as a continuous variable, but in the other study, age was as 
a grouped variable; this difference may cause heterogeneity in meta-analysis with meta-
regression (van Houwelingen, Arends, & Stijnen, 2002). In this meta-regression analysis, 
I planned to use regions and ethical groups as covariates. The linear model for regression 
was as follows; 




The is the effect size in the study i, the ,  are the unknown regression 
coefficients, and , …,  are the predictors value for study i (van Houwelingen et al., 
2002).  
Fixed Effects Model  
 In the fixed-effect analysis, the assumption was based on the same effect size in 
all studies, and the summary effect was an estimation of this common effect size (mean 
of the effect sizes). The variation between studies was used to define the sampling error, 
which was an error in estimation of effect size (Borenstein et al., 2009).  
 
The individual study effects were normally distributed with a mean of  and, in 
the variance of  , it is known for individual studies (Figure 11). The Shape 1 






Figure 11. The sample of the observed effect, the fixed effect model. The fixed model is 





In the fixed-effect model, the hypothesis test is 0 effect in every study. The 
statistical formula is as follows: 
Z-value to test the null hypothesis 
 
The M value is weighted mean, which calculated as 
 
The weight (W) for each study calculated as 
=  
Where is the within-study variance for each study i. 
The SEM is the standard error of the summary effect, the square root of the variance, as 
follows: 
SEM =  
The confidence intervals (95%) calculated as 
Lower limit, LLM = M – 1.96 × SEM 




Random Effects Model 
 In the random-effects analysis, the assumption was based on effect size, which 
varies from study to study. This study-to-study effect size variation represents a random 
sample of the effect sizes. In the random-effects analysis, the weighting strategy makes 
more balance of weighting on studies than in a fixed-effect analysis. The effect size is 
similar, but not identical among studies. Figure 12 (Borenstein et al., 2009) shows a 
random effects model. 
The hypothesis in the random-effects is zero for the mean effect (summary 
effect), as is listed in the following equation: 






Figure 12. The sample of the observed effect, the random effect model. The true effect 
Ɵ1 samples from a distribution of mean µ, and variance of  . The observed effect (T1) 




A test of the hypothesis is estimated at a Z-value with a value of 0 for mean effect 
(µ). The   is weighted mean computed as 
 
 
The  is the weighted assigned (variance inverse) to each study calculated as follows: 
=  
The = + T2, and the is within-study variances, and T2 is the between-study 
variance. 
In a comparison of random-effects and fixed-effect meta-analysis, a fixed-effect is 
used to estimate summary effect based on a common single effect to every study, but in 
random-effects, the estimation of effect summary is based on the mean of the distribution 
of effects in all studies. The results of random-effect analysis would generalize to the 
same scenarios. 
Multiple Testing Adjustments (Type I Error) 
This study involved multiple testing. Each gene’s polymorphism has five related 
genetic model analysis that, in each analysis, commonly involves a mutated allele 
(Conneely & Boehnke, 2010). There is not a routine multiple testing adjustment in 
systematic reviews, but there are only some single studies that would be subject to 




adjustment for combined three genes (MTHFR, MTR, and MTRR). In this study, each 
gene polymorphism had five related analyses, which would be subject to multiple testing 
adjustments. Through this multiple testing adjustment, for each polymorphism with five 
related analysis, I used the Holm (Step-down Bonferroni) method to adjust the multiple 
testing analysis (Aickin & Gensler, 1996). 
Sensitivity Analysis 
 Sensitivity analysis is used to determine the robustness of the findings. It is 
important to know how the results will change if I changed the aspects of data or 
analysis, such as criteria of including studies, changes in assumptions, or type of effect 
size (from OR to relate risk or p-value). In this study, the sensitivity analysis was used to 
remove individual study (repeatedly) on each pass to show how removing it affected the 
results (Borenstein et al., 2009).  
Forest Plot 
 A forest plot is used to interpret statistics in context. In a meta-analysis, a forest 
plot shows the effect size of individual studies, including its confidence interval as well 
as the summary effect. In this study, the forest plot showed the conceptual issues as the 
OR for each study with its boundaries of confidence interval plus the summary effect and 
its boundaries at the end, fixed, and random model (Borenstein et al., 2009). The value of 
summary effects and fixed and random models in a forest plot are unadjusted values. The 






A funnel plot is a diagnostic tool used for examining bias in the meta-analysis. It 
is an estimation of effect size versus the standard error, which in some studies is the 
effect size versus the sample size. In this study, the horizontal axis was the log of effect 
size (the log of OR), and the vertical axis was its standard error, in which the solid 
vertical line is the summary of effect sizes (fixed model) derived from a meta-analysis. 
This was a tool used to validate publication bias in a meta-analysis. The shape of the 
funnel, in the absence of bias, was symmetrical; in case of bias, the funnel plot would be 
skewed (Sterne & Harbord, 2004). 
Threats of Validity 
 The validity of the study refers to the researcher being able to answer the 
questions within the variables of the study (Reis & Judd, 2000). The validity is indicated 
as follows: the ability to generalize the results in the real world using the measurement 
strategy, the ability to generalize the results from the measurement and the study design, 
and the ability to determine that the results are accurate. In this study, the validity was 
based on answering the following questions: 
• Are the selected studies relevant to the inclusion criteria?  
• How is the quality of the selected studies?  
• What is the similarity of results from study to study?  
 The internal validity relates to causal relationships (Hogg & Cooper, 2007; Reis 
& Judd, 2000). To ensure internal validity, I looked at the measurements for variables. To 




populations (Reis & Judd, 2000). To determine the validity of a statistical conclusion, the 
validity of the procedures were examined in fixed and random effects models.  
Reliability 
 The reliability of a study is related to the quality of measurement: its repeatability 
and consistency of the measurement (Hogg & Cooper, 2007). In this study, the quality of 
measurement was related to the laboratory methods of gene mapping for those three gene 
polymorphisms in cases and controls. In addition, the measures of cases that related to the 
diagnoses of prostate cancer were affected by the quality of measurement. The measure 
of prostate cancer risk was based on two methods: chemicals and physical exams. The 
relationship of validity and reliability was based on the consistency and repeatability of 
the measurement. The consistency of the same or a close result in all repeated 
measurements made it a reliable and valid measure. 
Ethical Considerations 
This meta-analysis was based on the results of the individual studies that have 
been done before. Ethical considerations were important in the primary study. The 
selected studies in this meta-analysis were from different regions around the globe with 
different ethnic groups. In this meta-analysis, I planned to combine the results from each 
individual study; I assumed that each researcher obtained the permission of the people 
who participated in the research; I also assumed that each researcher obtained the 
appropriate institutional review board (IRB) approval before conducting the study. In this 
study, I worked directly with Walden IRB to ensure the correct ethical standards for 




research was based on ethical standards with Walden University and U.S. federal 
regulations. 
 Summary  
In this chapter, I explained the study design of this study and the statistical 
methods that were used to estimate the overall effect size, including its bounded 
confidence interval (CI). In a meta-analysis, the performance of regression depends on 
the individual number of studies that are involved in the analysis. In this meta-analysis, a 
unit of analysis was the individual study. As more studies were involved to the combine 
results, the power of the test becomes a more accurate result. The effect size of each 
study was OR, which was calculated from the genotype and the allele frequencies in each 
study. The definitions of dominant, codominant, and recessive models were explained, as 
well as how I represented them in the analysis. I explained the heterogeneity analysis to 
estimate the variation between studies and the fixed and random effects model to estimate 
the overall size effect and its CI boundaries. The validity and reliability concepts were 
explained in this chapter, including a sensitive analysis regarding the robustness of the 
outcome. I explained the concepts of forest and funnel plot in this meta-analysis study. 
In the next chapter, I present the results of estimations. I focuse on the outcomes. I 




Chapter 4: Results 
Introduction 
In this chapter, I present the results of the statistical analysis of the data from 20 
collected studies via charts, graphs, and tables. The number of individual studies was 
different in each genetic polymorphism. Prostate cancer is the second leading cause of 
cancer death among men after lung cancer. The purpose of this study was to examine 
gene-prostate cancer association. I examined the association of prostate cancer with three 
one-carbon metabolism gene polymorphisms (MTHFR, MTR, and MTRR). The 
association in this study was examined by a meta-analysis method.  
The research questions regarded the association between selected genotypes and 
prostate cancer risk. 
1. Is there any significant association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk? 
H1o: There is no association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
H1a: There is an association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk. 
2. Are there any significant differences between regions of the globe due to 
gene-disease association? 
H2o: There are no differences between regions due to gene-disease association. 




3. Are there any significant differences between ethnic groups due to gene-
disease association? 
H3o: There are no differences between ethnic groups due to gene-disease  
H3a: There is a difference between ethnic groups due to gene-disease association. 
Methodology of Meta-Analysis 
A meta-analysis research combines multiple studies to determine results from a 
group of articles with a common hypothesis. The unit of meta-analysis is the study; 
increasing the number of studies increases the power of the test. The power of the test in 
a meta-analysis is greater than an individual study. All included studies were a case-
control study with a number of cases and controls in different geographical regions and 
ethnic groups. Although there may not be a matched case-control study, the statistical 
analysis was used to estimate the association between the risk of prostate cancer and one-
carbon, metabolism gene polymorphisms (MTHFR, MTR, and MTRR).  
Overview of Meta-Analysis 
 In this meta-analysis study, I examined the association between one-carbon, 
metabolism gene polymorphisms and the risk of prostate cancer. There were three genes 
involved in this study with their polymorphisms: MTHFR gene with two polymorphisms 
of C677T (rs1801133), A1298C (rs1801131), MTR gene with a polymorphism of 
A2756G (rs1805087), and MTRR with a polymorphism of A66G (rs1801394). The total 
number of samples for both groups of cases and controls in the 20 included studies were 
8,675 cases and 9,207 controls. These cases and controls were the combined samples 




some studies, the different genes had different numbers. In this meta-analysis, I 
conducted an analysis based on the results from each individual study: the result of effect 
size (OR) association and CI were at the 95 % level of the test. 
Data Collection 
The data were collected from 20 individual studies from the years 2000 to 2014 
with the number of cases and controls in variants and wild genotypes. The wild 
genotypes were those genes without mutation, and the variant genotypes were those 
genes with mutation. The analysis was on the raw collected data. Although each 
individual study had an effect size and its CI results in their article, the size effect and its 
boundaries were estimated based on an OR formula for a case-control study. The general 
formula for OR estimation and its confidence intervals were presented in Chapter 3. Each 
individual study was conducted in a different region using various ethnic groups. In this 
study, I estimated the significant differences between the studies regarding these two 
variables (regions and ethnic groups).  
Eligibility: Inclusion/Exclusion Criteria 
The basis of eligibility criteria was on studies testing relationships between one-
carbon, metabolism gene polymorphisms (MTHFR, MTR and MTR) and prostate cancer 
risk. According to meta-analysis method, the results of this study should be able to be 
generalized to the real world, due to the validity of the study. The inclusion criteria 
involved defining the subject based on the study design. The individual study included 
had to have an explanation of the method used to obtain the results, and the article also 




ORs and CI boundaries, and the details of the data collection. The exclusion criteria were 
those studies with a defined subject and a lack of needed information. There were some 
studies in languages other than the English language, which were translated to English 
and were included in this study.  
In the MTHFR gene, there was a total number of 20 individual studies involved in 
C667T polymorphism with a total of 8,675 cases and 9,207 control participants in each 
group of studies. In the MTHFR gene, the A1298C polymorphism, 11 studies were 
included in the analysis, of which there were 3,026 cases and 3,754 control participants 
included in the analysis. The MTR gene, A2756G polymorphism, had four included 
studies with a total number of 701 case participants and the total number of 739 control 
participants. The MTRR gene, A66G polymorphism, included four studies with the total 
of 698 case and 737 control participants.  
Data Analysis 
 The data analysis of this meta-analysis study was based on a quantitative 
component of independent studies to yield an overall OR of the genotype-prostate cancer 
association. The analysis for this study included a step-by-step process. At first, the 
sample size in each individual study for both groups, cases and controls, was indicated by 
each genotype and allele frequencies. In the second step, I analyzed the homogeneity 
between studies by Q value and I2 estimation and then a fixed and random effect models 
for the overall size effect estimation. A funnel plot was used to examine the publication 
bias to ensure the validity of the results of each individual study. In the fixed-effects 




study variance was examined. In the random-effects model, the results were generalized 
to other studies where within and between studies variations were examined.  
 The meta-regression analysis helps to understand the source of variation that is 
indicated by the homogeneity test. In this meta-analysis, a meta-regression analysis was 
conducted after significant value for homogeneity was reached. The meta-regression 
analysis showed the related variation among the region of studies or the related variation 
among the different ethnic groups. The regions were in three groups of continents: 
America, Europe, and Asia. The ethnic groups were in four groups of Caucasian, African 
American, Asian, and Spanish. The forest plot in-text results show a general view of each 
individual study’s effect size and its boundaries, in addition to the overall size effect.   
Homogeneity 
 The homogeneity analysis tests the variation of effect size in different studies. In 
this meta-analysis, the variation of estimated OR within and between 20 selected 
individual studies was of concern. The homogeneity test was based on a Q statistical test 
with a chi-square distribution and degree of freedom, which valued the total number of 
study minus 1 (df =19). The description of variation percentage of homogeneity was 
calculated by I2, which indicates the percentage of variation related to the homogeneity 
rather than by chance. A I2close to 0 means the variation in effect size is due to sampling 
error within studies, and a value of close to 100 means a high heterogeneity among effect 





 The publication bias included the articles that were published rather than those not 
published among the total available studies. I showed the publication bias by a funnel 
plot. The funnel plot is a visual tool to show the biases in this meta-analysis, and it 
described the eligible selected studies involved in this meta-analysis study. The results of 
a funnel plot from small studies will typically be wide at the bottom of the graph and will 
be narrow at the bottom from large studies. The largest studies have the smallest value on 
the vertical axis (standard error of log odds ratios). The funnel plot will look like a 
symmetrical in absence of publication bias (Sterne & Harbord, 2004).    
Weights 
 The weighting strategies in this meta-analysis were based on two methods of 
variance estimation, within- and between-studies variances. The inverse variance method 
is common in meta-analysis studies. In the fixed effect model, the weight is inversely 
proportional to the within-study variance, and in the random model the weight is the 
inverse of the sum of the within-plus-between studies variances (Pigott, 2012).   
Validity 
The validity of this meta-analysis was based on questions asked in each individual 
study. Each individual study contained the same inclusion and exclusion criteria as this 
meta-analysis study. The validity of each included individual study was based on the 
study design and the performance of analytic process of each study. The research 
question in each individual study was in line with the goal of this meta-analysis on gene-





The results of this study were based on the results of statistical procedures on the 
association between prostate cancer risk and different alleles and genotype frequencies 
among selected populations in different regions, from 20 individual selected studies. The 
regions were subgroups in three continents: America, Europe, and Asia. The important 
issues in the analysis regarding different regions were related to different ancestry in the 
regions. The incidence rate of prostate cancer is different in different regions, such as 
213.7 in North America, Western Europe 167.9, and 133.2 in Asia (Dorr et al., 2013). 
The different ancestry may affect the genotype because they had a different 
environmental effect on the gene-environment interaction. For this reason, I tested 
different ancestries’ and regions’ associations with prostate cancer risk. 
The results are presented in subgroups of three different genes: MTHFR, MTR, 
and MTRR; the MTHFR gene sub grouped in two polymorphisms of C667T and 
A1298C. In the analysis, each polymorphism had its own results of test of homogeneity, 
fixed and random effects, meta-regression, forest plot, and funnel plot. The meta-
regression analysis did not show in some of the analysis because of the value of the Q 
statistic, in cases where the value of Q test result was smaller than the degree of freedom. 
A multiple test adjustment, due to Type I error, was applied in each polymorphism 
analysis. The Holm-Bonferroni multiple testing corrections was applied for fixed and 
random models of each polymorphism, which had five related analyses. The study weight 





 The methylenetetrahydrofolate reductase (MTHFR) gene is involved in folate 
metabolism and has two polymorphisms: C677T (rs1801133) and A1298C (rs1801131). 
The C677T polymorphism. In this study, the C677T polymorphism was in four 
subgroups of T Allele versus the C Allele, the genotype of TT versus CC, the genotype of 
CT versus CC, recessive model, and dominant model. 
The T allele versus C allele. Table 2 shows the results of the homogeneity test 
analysis based on 18 eligible included studies. Table 6 shows a significant heterogeneity 
among effect sizes (P<0.05), which may be evidence of heterogeneity related to regions 
or ethnic groups where the study took place. The I2 is another index of heterogeneity with 
57.45 % of the variation being due to the effect sizes rather than sampling variance, a 
moderate degree of heterogeneity.  
Table 2 
Test for Homogeneity of Effects, Allele T vs. C 
Q df ProbQ I2 
39.95 17 0.0013 57.45 




Table 3 shows the results of analysis in both fixed and random models. The 
fixed effect model indicates a significant association (p<0.001) between Allele 
T frequency and prostate cancer risk, but the random model indicates an 
association on the border of the significant (p=0.051). The OR indicates an 
inverse association of Allele T frequency and prostate cancer risk.  
Table 3 
 
Summary Effect Size, Allele T vs. C  






 p-value Adjusted 
p-value 
Fixed  0.92 0.88 0.97  0.0009 0.0027 
Random  0.91 0.83 1.00  0.0513 0.1539 
Note. The summary effect size of MTHFR gene, C667T polymorphism, Allele T vs. C 
Figure 13 displays a publication bias by a funnel plot. The solid vertical line 
represents a summary of size effect, a log-OR derived using fixed-effect meta-analysis. 
This figure shows that there may be a slight evidence of publication bias, at the right 
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Figure 13. Funnel plot for risk of prostate cancer data, Allele T vs. C solid line is fixed 
effect model. 
 
The overall effect size, based on the forest plot, shows a slight inverse association 






Figure 14.Forest plot of the association under allele T vs. C model 
 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Allele T vs. C  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.18 0.16 1.09 0.29 
Region 1 -0.13 0.07 -1.86 0.08 
Ethnicity 1 -0.00 0.06 -0.02 0.98 
Note. The summary of MTHFR gene, C667T polymorphism, Allele T vs. C 
Figure 15 shows the log OR of the study decreased by the region from America to 





Figure 15.Plot of observed effect size for the risk of prostate cancer data against Allele T 
frequency. 
 
The genotype TT versus CC. The heterogeneity of association of effect sizes 
among studies, between genotype TT and prostate cancer risk, is small (28.54 %) and not 






Test for Homogeneity of Effects, Genotype TT vs. CC 
Q df ProbQ I2 
23.79 17 0.13 28.55 
Note. The homogeneity results of MTHFR gene, C667T Polymorphism, Genotype TT vs. 
CC 
 
Although the results of heterogeneity were not significant (Table 5), it may be due 
to the result from the fixed effect model. The results from the random model show the 
same result as the fixed effect model due to significant association. The fixed effect 
model shows (Table 6) a significant association between TT genotype frequency and 
prostate cancer risk (p<0.05), which it is a significant association in the random model 
too (P<0.05). 
 
Table 6  
Summary Effect Size, Genotype TT vs. CC  






 p-value Adjusted 
p-value 
Fixed  0.81 0.73 0.91  0.0002 0.0010 
Random  0.78 0.66 0.92  0.0035 0.0175 






Figure 16 shows an asymmetric shape. The publication bias in Figure 16 is on 
missing studies in the top right side of the figure. Although the density of studies is more 
on the upper left hand side of the funnel plot, there are still missing studies on the right 
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 Table 7 indicates no relationship between regions and Genotype TT frequency; 
there is not a significant association between prostate cancer and regions or ethnic 
groups, as heterogeneity was not significant (p=0.13).  
Table 7 
Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Genotype TT vs. CC  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.18 0.27 0.68 0.50 
Region 1 -0.13 0.15 -0.85 0.41 
Ethnicity 1 -0.15 0.15 -0.97 0.35 
Note. The summary of MTHFR gene, C667T polymorphism, and Genotype TT vs. CC 
Figure 17 shows an inverse significant association between the overall OR of 






Figure 17. Forest plot of the association under Genotype TT vs. CC model. 
 
 The genotype CT versus CC. The test of homogeneity (Table 8) shows a highly 
significant heterogeneity among studies’ effect sizes (P<0.001) with a moderated degree. 
Table 8 
Test for Homogeneity of Effects, Genotype CT vs. CC 
Q df ProbQ I2 
53.70 18 <.0001 66.48 
Note. The homogeneity results of MTHFR gene, C667T Polymorphism, and Genotype 
CT vs. CC 
 
 There was not a significant association between genotype CT frequency and 




Table 9  
Summary Effect Size, Genotype CT vs. CC  






 p-value Adjusted 
p-value 
Fixed  0.97 0.91 1.03  0.34 0.34 
Random  0.96 0.83 1.12  0.63 0.70 
Note. The summary effect size of MTHFR gene, C667T polymorphism, Genotype CT vs. 
CC 
 
The funnel plot regarding the publication bias on genotype CT versus CC shows some 
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 Figure 19 shows no significant overall estimation of OR for both fixed and 
random models.  
 
Figure 19. Forest plot of the association under Genotype CT vs. CC model. 
 





Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnic Groups, Gynotype CT vs. CC  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.25 0.28 0.90 0.38 
Region 1 -0.16 0.12 -1.36 0.19 
Ethnicity 1 0.03 0.11 0.26 0.80 
Note. The summary of MTHFR gene, C667T polymorphism, and Genotype  CT vs. CC 
 
 The recessive model (TT vs. CT+CC). The homogeneity test does not show a 
significant heterogeneity among studies (Table 11), a small degree of heterogeneity 
among effect sizes (27.57%). 
Table 11 
Test for Homogeneity of Effects, Recessive Model (TT vs. CT+CC) 
Q df ProbQ I2 
23.47 17 0.1344 27.58 
Note. The homogeneity results of MTHFR gene, C667T Polymorphism, and recessive 
model (TT vs. CT+CC) 
 
 The results from the fixed and random effect models shows a highly significant 
effect sizes for both models at 0.05 levels of test (p<0.05; Table 12). This significant 




Table 12  
Summary Effect Size, Recessive Model (TT vs. CT+CC)  






 P-value Adjusted 
p-value 
Fixed  0.83 0.75 0.92  0.0003 0.0012 
Random  0.79 0.68 0.93  0.0035 0.0175 
Note. The summary effect size of MTHFR gene, C667T polymorphism, and recessive 
model (TT vs. CT+CC) 
 
 Figure 20 shows a publication bias at the right part of the plot. The population 
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Figure 21 indicates an overall significant association between the recessive model 
and a reduction of the risk of prostate cancer. 
 
Figure 21. Forest plot of the association under genotype recessive model. 
 
 Table 13 shows that there was not any significant relationship between regions 







Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Recessive Model (TT vs. CT+CC)  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.08 0.26 0.31 0.76 
Region 1 -0.10 0.15 -0.64 0.53 
Ethnicity 1 -0.10 0.15 -0.67 0.51 
Note. The summary of MTHFR gene, C667T polymorphism, and recessive model (TT vs. 
CT+CC) 
 
The dominant model (CT+TT) vs. CC. Table 14 indicates that there was a highly 
significant heterogeneity among effect sizes (P<0.001); the index value of heterogeneity 
was moderate (65.49%). 
Table 14 
Test for Homogeneity of Effects, Dominant Model (CT+TT) vs. CC 
Q df ProbQ I2 
52.15 18 <.0001 65.49 
Note. The homogeneity results of MTHFR gene, C667T polymorphism, and dominant 
model (CT+TT) vs. CC 
 
Table 15 shows no significant association between the dominant model and the 




Table 15  
Summary Effect Size, Dominant Model (CT+TT) vs. CC  






 p-value Adjusted 
p-value 
Fixed  0.94 0.88 1.00  0.05 0.10 
Random  0.94 0.82 1.07  0.35 0.70 
Note. The summary effect size of MTHFR gene, C667T polymorphism, and dominant 
model (CT+TT) vs. CC 
 
Figure 22 was almost symmetric, just short of small number of studies at the right 
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Figure 23 indicated no significant association between the dominant model and 
the risk of prostate cancer, but there was a border significant association (p=0.05) for the 
fixed effect model. 
 
Figure 23. Forest plot of the association under dominant model. 
 
 Table 16 shows that there was not an explanation of variation of effect size related 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Dominant Model (CT+TT) vs. CC  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.26 0.26 1.00 0.33 
Region 1 -0.18 0.11 -1.66 0.12 
Ethnicity 1 0.01 0.08 0.18 0.86 
Note. The summary effect size of MTHFR gene, C667T polymorphism, and dominant 
model (CT+TT) vs. CC 
 
 The A1298C polymorphism. In this study, the polymorphisms were analyzed in 
five subgroups of Allele C versus Allele A, Genotype CC versus AA, Genotype AC 
versus AA, recessive model, and dominant model. 
 The C Allele versus A allele. There was a significant heterogeneity of effect sizes 
at 0.05 levels of test (P<0.05; Table 17), which indicated a moderate degree of 
heterogeneity. There was a 52.63 % of heterogeneity in this study due to heterogeneity 






Test for Homogeneity of Effects, Allele C vs. A 
Q df ProbQ I2 
19 9 0.03 52.63 
Note. The homogeneity results of MTHFR gene, A1298C polymorphism, Allele C vs. A 
 Table 18 indicates that there was not a significant association between the Allele 
C and risk of prostate cancer (P>0.05). 
Table 18  
Summary Effect Size, Allele C vs. A  






 p-value Adjusted 
p-value 
Fixed  1.04 0.96 1.13  0.36 0.72 
Random  1.06 0.93 1.22  0.37 1.00 
Note. The summary effect size of MTHFR Gene, A1298C Polymorphism, and 
Allele C vs. A 
 
Figure 24 shows a slight publication bias on the bottom left side of the plot, with a 
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Figure 24. Funnel plot for risk of prostate cancer data, Allele C vs. A. 
   
Figure 25 shows no significant association between the overall OR of Allele C 





Figure 25. Forest plot of the association under Allele C vs. A model. 
 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Allele C vs. A  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.04 0.23 0.17 0.87 
Region 1 0.02 0.11 0.22 0.83 
Ethnicity 1 -0.02 0.11 -0.16 0.88 
Note. The summary of MTHFR gene, A1298C polymorphism, and Allele C vs. A 
 
The Gynotype CC vs. AA. Table 20 shows a moderate degree of heterogeneity of 
effect sizes (I2=31.40%). 
The estimation of the association between Genotype CC frequency and risk of 
prostate cancer shows a slight association with the fixed effect model with unadjusted 
value (p=0.08), but there was no significant association at the random effect model 
(p>0.05; Table 21). 
Table 20 
Test for Homogeneity of Effects, Gynotype CC vs. AA 
Q df ProbQ I2 
13.12 9 0.16 31.42 
Note. The homogeneity results of MTHFR gene, A1298C polymorphism, and Gynotype 






Table 21  
Summary Effect Size, Genotype CC vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.18 0.98 1.41  0.08 0.24 
Random  1.14 0.89 1.46  0.30 1.00 
Note. The summary effect size of MTHFR Gene, and A1298C Polymorphism, 






 Figure 26 showed a publication bias with missing studies on the right side of the 
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Figure 26. Funnel plot for risk of prostate cancer data and Gynotype CC vs. AA. 
 
 
 Figure 27 describes the positive association between Genotype CC frequency and 





Figure 27. Forest plot of the association under Genotype CC vs. AA model. 
 
 Table 22 does not show any significant association that the variation between 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Gynotype CC vs. AA  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 0.05 0.39 0.13 0.90 
Region 1 0.03 0.17 0.15 0.88 
Ethnicity 1 0.03 0.22 0.12 0.90 
Note. The summary of MTHFR gene, A1298C polymorphism, and Genotype CC vs. AA 
 The Genotype AC vs. AA. Table 23 shows a significant value of the homogeneity 
test (p<0.05), with a moderate degree of heterogeneity. There was a significant 
heterogeneity in the effect size of the different studies (I2=60.66). 
Table 23 
Test for Homogeneity of Effects, Genotype AC vs. AA 
Q df ProbQ I2 
22.88 9 0.007 60.66 
Note. The homogeneity results of MTHFR gene, A1298C polymorphism, and Genotype 
AC vs. AA 
 
 Table 24 shows a highly significant effect size (p<0.05), but the random effect 




Table 24  
Summary Effect Size, Genotype AC vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.24 1.11 1.38  0.0001 0.0005 
Random  1.10 0.90 1.34  0.36 1.00 
Note. The summary effect size of MTHFR Gene, A1298C Polymorphism, and 
Genotype AC vs. AA 
 
 
 Figure 28 shows asymmetry and that there were some missing studies at the top 
right side of the graph, studies with more log OR than the overall size effect, and low 
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 Figure 29 shows a significant positive association by fixed effect model, but no 





Figure 29. Forest plot of the association under Genotype AC vs. AA model. 
 
Table 25 indicates a significant variance in effect size that related to the regions of 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Genotype AC vs. AA  
  Parameter Estimate   




t Value Pr>|t| 
Intercept 1 0.51 0.12 4.26 0.004 
Region 1 -0.28 0.06 -4.70 0.002 
Ethnicity 1 0.10 0.06 1.69 0.136 
Note. The summary of MTHFR gene, A1298C polymorphism, and Genotype AC vs. AA 
 Figure 30 shows a scatter plot of effect size against regions, which was evidenced 
in the relationship between regions and effect size variance. The effect size decreased 
from the American region to the Asian region; the samples in Asia had an inverse 





Figure 30. Plot of observed effect size for the risk of prostate cancer data against 
Genotype AC frequency. 
 
The recessive model (CC vs. AC+AA). Table 26 shows no signs of heterogeneity 
of effect size. 
Table 26 
Test for Homogeneity of Effects, Recessive Model (CC vs. AC+AA) 
Q df ProbQ I2 
15.19 9 0.09 40.76 
Note. The homogeneity results of MTHFR Gene, A1298C Polymorphism, and recessive 




 The test of association between recessive model and prostate cancer risk for both 
fixed and random models shows no significant association (Table 27). 
Table 27  
Summary Effect Size, Recessive Model (CC vs. AC+AA)  






 p-value Adjusted 
p-value 
Fixed  1.07 0.90 1.27  0.42 0.72 
Random  1.07 0.83 1.39  0.59 1.00 
Note. The summary effect size of MTHFR Gene, A1298C Polymorphism, and 
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Figure 31. Funnel plot for risk of prostate cancer data, recessive model (CC vs. AC+AA). 
  
Figure 32 shows an overview of odds of studies and the overall effect size for 
both fixed and random effects with no significant association between the recessive 





Figure 32. Forest plot of the association under a recessive model. 
 
 Table 28 shows no relationship between regions and ethnic groups to the variation 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Recessive Model (CC vs. AC+AA)  
  Parameter Estimate   




T Value Pr>|t| 
Intercept 1 -0.22 0.39 -0.57 0.59 
Region 1 0.16 0.17 0.95 0.37 
Ethnicity 1 -0.01 0.21 -0.04 0.97 
Note. The summary of MTHFR gene, A1298C polymorphism, recessive model (CC vs. 
AC+AA) 
 
 The dominant model (AC+CC) vs. AA. Table 29 shows a highly significant 
heterogeneity between studies (58.21%), a large degree of heterogeneity of effect size. 
Table 29 
Test for Homogeneity of Effects, Dominant Model (AC+CC) vs. AA 
Q df ProbQ I2 
23.93 10 0.008 58.21 
Note. The homogeneity results of MTHFR Gene, A1298C Polymorphism, dominant 
model (AC+CC) vs. AA 
 
 Table 30 shows a highly significant association between dominant model and 




Table 30  
Summary Effect Size, Dominant Model (AC+CC) vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.24 1.12 1.36  <.0001 0.0005 
Random  1.15 0.96 1.36   0.13 0.65 
Note. The summary effect size of MTHFR Gene, A1298C Polymorphism, 
dominant model (AC+CC) vs. AA 
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 Figure 34 shows no significant association between the dominant model and 
prostate cancer risk. 
 
Figure 34. Forest plot of the association under dominant model. 
 
 
Table 31 shows that there was not any relationship between the variance of the 





Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Dominant Model (AC+CC) vs. AA  
  Parameter Estimate   




t Value Pr>|t| 
Intercept 1 0.42 0.21 2.03 0.08 
Region 1 -0.16 0.08 -1.88 0.09 
Ethnicity 1 0.01 0.06 0.23 0.82 
Note. The summary effect size of MTHFR Gene, A1298C Polymorphism, dominant 
model (AC+CC) vs. AA 
MTR (A2756G) 
 In this study, the association of the MTR gene, including A2756G (rs1805087) 
polymorphism with prostate cancer risk, was analyzed. The number of studies was not 
large enough to make a more accurate result, but the results provide information for 
future research.    
 The G Allele versus A Allele. Table 32 shows no significant results of 
homogeneity on the effect size of studies.   
Table 32 
Test for Homogeneity of Effects, Allele G vs. A 
Q df ProbQ I2 
2.49 2 0.29 19.68 




 The results of fixed and random model analysis (Table 33) show no significant 
effect sizes.  
Table 33  
Summary Effect Size, Allele G vs. A  






 p-value Adjusted 
p-value 
Fixed  1.17 0.89 1.54  0.27 1.00 
Random  1.19 0.86 1.65  0.29 1.00 
Note. The summary effect size of MTR Gene, A2756G Polymorphism, Allele 
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Figure 35. Funnel plot for risk of prostate cancer data, Allele G vs. A. 
  
Figure 36 shows the individual studies, ORs, and CIs, plus the overall effect sizes 






Figure 36. Forest plot of the association under Allele G vs. A model. 
 
 The Genotype GG vs. AA. The homogeneity test does not come up with a result 
because the degree of freedom was more than the Q test result (Table 34). 
Table 34 
Test for Homogeneity of Effects 
Q df ProbQ I2 
1.23 2 0.54 Q<df 
Note. The homogeneity results of MTR Gene, A2756G Polymorphism, Genotype GG vs. 
AA 






Table 35  
Summary Effect Size, Genotype GG vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.26 0.61 2.62  0.53 1.00 
Random  1.26 0.61 2.62  0.53 1.00 
Note. The summary effect size of MTR Gene, A2756G Polymorphism, 
Genotype GG vs. AA 
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Figure 38 shows the effect sizes and their boundaries with the results of no 
significant association between Genotype GG and prostate cancer risk. 
 
Figure 38. Forest plot of the association under Genotype GG vs. AA. 
 
The Genotype AG vs. AA. Table 36 shows no results because of a lesser value of 
Q-test than df.  
Table 36 
Test for Homogeneity of Effects, Genotype AG vs. AA 
Q df ProbQ I2 
1.43 2 0.49 Q<df 
Note. The homogeneity results of MTR gene, A2756G polymorphism, Genotype AG vs. 
AA 
 There was no significant association of effect sizes and prostate cancer risk in 





Table 37  
Summary Effect Size, Genotype AG vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.13 0.81 1.58  0.48 1.00 
Random  1.13 0.81 1.58  0.48 1.00 
Note. The summary effect size of MTR Gene, A2756G Polymorphism, 
Gynotype AG vs. AA 
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Figure 40 shows the ORs and their boundaries, including both fixed and random 
effect sizes. 
 
Figure 40. Forest plot of the association under Genotype GG vs. AA. 
 
 The recessive model (GG vs. AA+AG). Table 38 does not show the homogeneity 
result of effect size because the value of the Q-test was less than df.  
Table 38 
Test for Homogeneity of Effects, Recessive Model (GG vs. AA+AG) 
Q df ProbQ I2 
1.29 2 0.52 Q<df 
Note. The homogeneity results of MTR Gene, A2756G Polymorphism, recessive model 
(GG vs. AA+AG) 
  





Table 39  
Summary Effect Size, Recessive Model (GG vs. AA+AG)  






 p-value Adjusted 
p-value 
Fixed  1.22 0.59 2.52  0.59 1.00 
Random  1.22 0.59 2.52  0.59 1.00 
Note. The summary effect size of MTR Gene, A2756G Polymorphism, 
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Figure 41. Funnel plot for risk of prostate cancer data, recessive model (GG vs. 
AA+AG). 
 





Figure 42. Forest plot of the association under recessive model (GG vs. AA+AG). 
 
 The dominant model (AG +GG vs. AA). Table 40 shows no significant result 
because the value of the Q-test was less than df. Table 41 shows no significant 
association between dominant model and prostate cancer risk.  
Table 40 
Test for Homogeneity of Effects, Dominant Model (AG +GG vs. AA) 
Q df ProbQ I2 
2.32 3 0.51 Q<df 
Note. The homogeneity results of MTR Gene, A2756G Polymorphism, dominant model 






Table 41  
Summary Effect Size, Dominant Model (AG +GG vs. AA)  






 p-value Adjusted 
p-value 
Fixed  1.08 0.85 1.38  0.52 1.00 
Random  1.08 0.85 1.38  0.52 1.00 
Note. The summary effect size of MTR Gene, A2756G Polymorphism, 
dominant model (AG +GG vs. AA) 
 
 
Figure 43 shows missing studies on the left side of the graph with a low log of OR 
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Figure 43. Funnel plot for risk of prostate cancer data, dominant model (AG +GG 
vs. AA). 






Figure 44. Forest plot of the association under dominant model (AG +GG vs. AA). 
 
MTRR (A66G) 
 This study included analysis of the MTRR Gene, A66G Polymorphism 
(rs1801394). Although the number of studies was not enough for an accurate result, the 
results of this study can be used for the future studies.  
 The G Allele versus A Allele. Table 42 does not show a significant effect; the 
degree of homogeneity of effect size was small (I2 <50%). 
 
Table 42 
Test for Homogeneity of Effects 
Q df ProbQ I2 
3.04 2 0.22 34.21 
Note. The homogeneity results of MTRR Gene, A66G Polymorphism, Allele G vs. A 




Table 43  
Summary Effect Size, Allele G vs. A  






 p-value Adjusted 
p-value 
Fixed  0.95 0.80 1.14  0.60 1.00 
Random  0.94 0.75 1.18  0.61 1.00 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, Allele 
G vs. A 
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 Figure 46 shows the ORs and the boundaries of the weight of studies including 
the overall size effect as a square shape. 
 
 
Figure 46. Forest plot of the association under Allele G vs. A model. 
 
 The Genotype GG vs. AA. Table 44 shows a significant result with the moderate 
degree of homogeneity of effect size. 
Table 44 
Test for Homogeneity of Effects, Genotype GG vs. AA 
Q df ProbQ I2 
6.10 2 0.05 67.21 
Note. The homogeneity results of MTRR Gene, A66G Polymorphism, Genotype GG vs. 
AA 
 





Table 45  
Summary Effect Size, Genotype GG vs. AA  






 p-value Adjusted 
p-value 
Fixed  0.87 0.55 1.38  0.56 1.00 
Random  0.70 0.29 1.72  0.44 1.00 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, 
Genotype GG vs. AA 
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Figure 47. Funnel plot for risk of prostate cancer data, Genotype GG vs. AA. 
 
 
 Figure 48 shows the individual OR and their boundaries, including fixed and 





Figure 48. Forest plot of the association under Genotype GG vs. AA. 
 
The Genotype AG vs. AA. Table 46 shows a significant heterogeneity of effect 
size with a large degree of heterogeneity (p<0.05).   
Table 46 
Test for Homogeneity of Effects, Genotype AG vs. AA 
Q df ProbQ I2 
13.63 2 0.0011 85.33 
Note. The homogeneity results of MTRR Gene, A66G Polymorphism, Genotype AG vs. 
AA 
 





Table 47  
Summary Effect Size, Genotype AG vs. AA  






 p-value Adjusted 
p-value 
Fixed  0.97 0.72 1.31  0.84 1.00 
Random  0.63 0.25 1.58  0.33 1.00 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, 
Genotype AG vs. AA 
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Figure 50 shows the OR and their boundaries of effect sizes, including the overall 
effect sizes for both fixed and random models.  
 
Figure 50. Forest plot of the association under Genotype AG vs. AA. 
The recessive model (GG vs. AG+AA). Table 48 does not show a significant 
result because the Q-test value was smaller than df. 
 
Table 48 
Test for Homogeneity of Effects, Recessive Model (GG vs. AG+AA) 
Q df ProbQ I2 
0.33 2 0.85 Q<df 
Note. The homogeneity results of MTRR Gene, A66G Polymorphism, recessive model 
(GG vs. AG+AA) 
  




Table 49  
Summary Effect Size, Recessive Model (GG vs. AG+AA)  






 p-value Adjusted 
p-value 
Fixed  1.00 0.68 1.44  0.98 1.00 
Random  1.00 0.68 1.44  0.98 1.00 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, 
recessive model (GG vs. AG+AA) 
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 Figure 52 shows no significant association on recessive model and prostate cancer 
risk. 
 
Figure 52. Forest plot of the association under recessive model (GG vs. AG+AA). 
 
 
 The dominant model (AG+GG) vs. AA. Table 50 shows a highly significant 
heterogeneity with a large degree of heterogeneity of effect size (I2=77.53%).  
 
Table 50 
Test for Homogeneity of Effects, Dominant Model (AG+GG) vs. AA 
Q df ProbQ I2 
13.36 3 0.0039 77.54 
Note. The homogeneity results of MTRR Gene, A66G Polymorphism, dominant model 
(AG+GG) vs. AA 
 
Table 51 does not show a significant association of effect sizes on both fixed and 




Table 51  
Summary Effect Size, Dominant Model (AG+GG) vs. AA  






 p-value Adjusted 
p-value 
Fixed  1.01 0.80 1.28  0.91 1.00 
Random  0.82 0.48 1.41  0.48 1.00 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, 
dominant model (AG+GG) vs. AA 
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 Figure 54 shows no significant association between dominant model and prostate 
cancer risk. 
 
Figure 54. Forest plot of the association under dominant model (AG+GG) vs. AA. 
 
Table 52 shows that there was not an association of variation of effect size related 






Result of Weighted Multiple Regression Analysis of Effect Size on Region of Study and 
Ethnicity Groups, Dominant Model (AG+GG) vs. AA  
  Parameter Estimate   




t Value Pr>|t| 
Intercept 1 -0.33 3.04 -0.11 0.93 
Region 1 0.28 0.91 0.31 0.81 
Ethnicity 1 -0.14 0.63 -0.22 0.86 
Note. The summary effect size of MTRR Gene, A66G Polymorphism, dominant model 
(AG+GG) vs. AA 
 
Summary 
In this chapter, I presented the results of the statistical analysis based on the 
research questions and the association of prostate cancer risk with the four genes of 
MTHFR with two polymorphisms (C667T and A1298C), MTR (A2756G 
polymorphism), and MTRR (A66G polymorphism). In the process of testing, I first 
estimated the variation of effect size by a homogeneity test and then estimated the overall 
effect size of both fixed and random models. In the case of heterogeneity of effect size, a 
researcher usually looks at the overall randomness of the model. In this study, I placed 
both fixed and random model results into a table. 
I found that there was a highly significant association between variant allele 




risk (P<0.05) in both fixed and random models. The homogeneity test for these 
associations was significant (p<0.05) with a moderate degree of heterogeneity. There was 
a highly significant association of Genotype TT and recessive model (TT vs. [CT+CC)]) 
with a decrease in prostate cancer risk in both fixed and random models. The sensitivity 
analysis revealed significance for Allele T, Genotype TT, and recessive model (TT vs. 
[CT+CC]) with a decrease in prostate cancer risk.   
In A1298C Polymorphism, there was a significant association between Genotype 
AC and an increased risk of prostate cancer (p<0.05), and the same significant increase of 
risk in the dominant model in the fixed effect model only. The sensitivity analysis 
revealed a significant association between Genotype AC and an increased risk of prostate 
cancer in the fixed effect model only. The results showed a significant association 
between regions and risk of prostate cancer on Genotype AC versus AA in A1298C 
polymorphism of the MTHFR gene. The region and prostate cancer association showed a 
decrease of log ORs among Asian verses American (Figure 30) subjects. The number of 
samples used to test MTR and MTRR was small, and the related results were not 
significant, but a future researcher may examine this association. In Chapter 5, I present 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
In Chapter 5, I discuss the study overview and results with conclusions and 
recommendations. This study involved 20 eligible articles of 2,800 reviewed studies from 
the years 2000 to 2014, based on inclusion and exclusion criteria. A total of 8,675 cases 
and 9,207 control participants were in the 20 involved studies with a common hypothesis 
on the association between one-carbon, metabolism gene polymorphisms (MTHFR, 
MTR, MTRR Gens) and prostate cancer risk.  
The Objectives 
The objective of this study was to examine the association between one-carbon 
metabolism gene polymorphisms and prostate cancer risk among men in the different 
regions of the world and from different ethnic groups. The results of this study could help 
meet the following long-term goals related to the prevention of prostate cancer:  
• To develop clinical methods in preventing prostate cancer risk at an early 
stage of the disease  
• To improve health care availability and accessibility for low-income 
families and those who need these services  
• To develop the health literacy and knowledge of the public on the benefits 
of prostate cancer prevention and prostate cancer screening  
• To recommend establishing policies on surveillance systems, practices, 




• To develop a positive change of people’s attitude and behavior regarding 
the early detection of prostate cancer disease, prevention, and course 
treatment strategies 
The prevention of prostate cancer at an early stage helps improve the quality of 
life in communities and increases life expectancy by decreasing the cost of treatment. 
Prostate cancer is one of the most serious diseases among males in the world, which 
affects life expectancy and life quality. In 2009, prostate cancer was the second leading 
cause of death among males in the United States (“CDC - Prostate Cancer,” n.d.). The 
most important aspect of treating  prostate cancer is diagnosis at an early stage (“CDC - 
Prostate Cancer,” n.d.). The gene-disease association studies were developed by 
clinicians to test the technologies and the methods of analysis to improve diagnosis. The 
technologies helped scientists to make accurate results of gene mapping due to the gene-
disease association (Gudmundsson et al., 2009).   
The association between one-carbon metabolism gene polymorphisms and 
cancers was studied previously (Suzuki et al., 2007, 2008; Theodoratou et al., 2012), but 
the individual studies left a gap in the literature that could be filled with a meta-analysis 
of relevant research. In this study, the association between one-carbon, metabolism gene 
polymorphisms and prostate cancer risk was examined to find the best course of 
treatment methods and to develop policies to prevent the disease among males who are at 
risk of the disease. The key findings are the decrease risk of prostate cancer with TT 




association was found in an increased risk of prostate cancer with AC genotype and 
dominant model in A1298C polymorphism.   
Interpretation of the Findings 
The findings of this study are related to the association of three selected genes 
(MTHFR, MTR, and MTRR) and prostate cancer risk. In addition, the findings of this 
study show an association between prostate cancer risk and different regions in the world. 
Gene-Prostate Cancer Association 
A human genome study could provide knowledge on reducing the incidence rate 
of diseases and promote health care and health services that benefit people. The gene and 
prostate cancer association was examined in previous studies (López-Cortés et al., 2013). 
The chromosomes or gene abnormalities that cause genetic diseases may or may not be 
transferred from parents to the offspring as an inherited disease (Frank, 2007). The gene-
gene and gene-environment association is a detection method that can be studied in future 
studies. The folate intake, dietary, and genetic linkage disequilibrium should also be 
examined for a gene-prostate cancer association (Shirai et al., 2002; Yeager et al., 2009). 
In this study, I examined three genes with their polymorphisms to determine if 
there was an association with prostate cancer risk. The genes studied in this study are 
involved in folate pathway, which are in DNA synthesis and methylation modification 
(Donkena et al., 2010). I examined the three following genes: MTHFR gene located at 
short arm of Chromosome 1, p36.3, Exon 4 with two polymorphisms C667T and 
A1285C; MTR gene located on long (q) arm of Chromosome 1 at Position of 43, Exon 




at Position 15.31 with A66G polymorphism. The results show that the MTHFR gene has 
an association with prostate cancer risk.   
Regions and Ethnic Groups 
The regions and ethnic groups are important in this study analysis because there 
was a different incidence rate of prostate cancer among regions (Figure 4) and ethnic 
groups (Crawford, 2003). People have different ancestry, which affects their genotype; 
different genotypes and environments effect (gene-environment interaction) make a 
different phenotype for people. These combinations of genotype and environment effect 
may affect a person’s lifestyle, as Grönberg (2003) mentioned in the incidence rate of 
prostate cancer among those men who moved to The United States from Japan. Grönberg 
indicated that each different group has different incidence rates of prostate cancer. 
Grönberg suggested a difference between ethnic groups who live in different 
geographical areas and prostate cancer incidence. When a Japanese group emigrated from 
Japan to the United States, their previous low incidence rate of prostate cancer changed to 
a higher incidence rate of prostate cancer in the new home (Grönberg, 2003). The results 
of the meta-analysis study result were in alignment with region-prostate cancer risk 
association.  
In this meta-analysis study, I examined the association between prostate cancer 
risk at different regions and ethnic groups on selected polymorphisms. I found a 
significant association between regions and prostate cancer risk on Genotype AC versus 
AA in A1298C Polymorphism of the MTHFR Gene. The AC Genotype frequency is 




risk of prostate cancer than those people who live in America. The results of this study 
are in alginment with studies by Li et al. (2013) and Ntais et al. (2003), who indicated 
less risk of prostate cancer for those who live in Asia than America. The gene frequency 
differences among different racial/ethical groups who live in different regions may be 
related to their diet and environmental factors. Future researchers should study gene-gene 
and gene-environmental interaction rch.  
There are ethical issues related to prostate cancer risk and prevention. I believe 
that males who are at an increased risk of prostate cancer may not wish to share their 
genetic prevalence with third parties, such as insurance companies or even their family 
due to future problems in their lives. Males at risk may not wish to inform their insurance 
companies because they may fear an increase in their insurance rate, and they may not 
wish to inform family because of the potential economic burden of death or inability to 
provide for the family. Finally, males at risk of prostate cancer may not wish to inform 
their employers because the employers may not wish to employ a person who has an 
increased risk for disease.  
There are also problems with the testing of prostate cancer among patients. 
Patients may experience stress when thinking about the physical exam (digital rectal 
exam), which is required to test prostate cancer diagnosis (“Information, Testing, 
Treatment, Research, Support Services - Prostate Cancer Canada,” n.d.). If a male has a 
gene linked to prostate cancer risk, he may avoid the stress associated with a physical 
exam because a physical exam is more painful for the patients (“Information, Testing, 




prostate cancer by a genetic screening could help patients lessen their pain and have more 
accurate results when combined with other tests. 
Limitations of the Study 
This study was limited to the information included in each eligible study in this 
meta-analysis. There was some publication bias in each eligible study, as some eligible 
studies were not published. This study was also limited to the data collected from the 
individual studies based on crude ORs because only some of them had adjusted data for 
covariates, such as folate intake or alcohol consumption (Johansson et al., 2007). The 
robustness of the statistical technique that they used was included in each individual 
study. Some of the researchers included a small sample size in their study, which affected 
the power of the test (López-Cortés, 2013). This study had the limitation of small sample 
size, but the results will help for future research.  
The unity of cases and control groups (matched case-control) in numbers and the 
quality of data collection were also another limitation to this study. The unity included 
related risk factors for prostate cancer. In some studies, the researcher did examine the 
effect of environmental factors, such as the folate intake, dietary intake, drinking, and 
smoking and the risk of prostate cancer, but others did not. Although I adjusted those 
environmental covariates by statistical methods, it was still a limitation to the study. The 
included studies were conducted in different geographical areas (different regions), which 
may have affected this analysis. Although I did examine the regional effect in this study 




The limitation of the multiplicity test came through this study. The multiple 
comparisons among hypothesis testing of these three genes (MTHFR, MTR, and MTRR) 
impacted the validity of each hypothesis testing due to Type I error inflation. The p-value 
adjustment method by the Holm (Step-down Bonferroni) method for the multiplicity test 
of individual polymorphism was estimated (Aickin & Gensler, 1996). The dependency 
and correlation among these three genes has not been reported yet, so the multiplicity test 
adjustment was not estimated for the three combined genes in this study. The multiplicity 
adjustment p-value will apply among these three genes if there is an approved result of 
linkage disequilibrium among them in future studies. The simulation method would help 
for an appropriate adjustment method of the gene-disease association.    
The strengths of this meta-analysis were in my ability to analyze and summarize a 
large amount of information from previous studies with a common hypothesis. This 
meta- analysis allowed for subgroup (regions) analysis. I clarified the heterogeneity 
between individual study results and did a subgroup analysis based on different regions 
of individual study. I considered the literature reviews in the studies and placed more 
attention on gene-gene and gene-environment interaction for future study. In this meta-
analysis study on the association between MTHFR, MTR, and MTRR genes and prostate 
cancer, I included more studies than others did. In this study, I increased the sample size 
to increase the power of the test, and I reduced false negative results.  
Recommendations  
The limitations of this study provide grounds for future studies. I used only 




gene polymorphism and the risk of prostate cancer, but they had different covariates 
involved in the analysis. Some of the scholars examined the folate intake association with 
the hypothesis plus other variables, but some did not include those variables. Future 
researchers should take into account the effect of the environment (variables) as well as 
group, age, nutrient intake, and family history in the target population.  
Future scholars should evaluate the association between folate intake levels and 
the risk of prostate cancer. I suggest that future studies include the ancestry of the 
involved people in the record. Although some of the included studies collected data from 
the U.S. or Canadian population, it would be important to know where future populations 
come from in Asia, Europe, or the Middle East. In addition, future scholars should record 
the chronic diseases in individual participants, such as diabetes, heart diseases, or other 
cancers. I recommend having a larger sample size in future studies to provide results that 
are more accurate. 
Epidemiology Recommendation 
One of the epidemiology recommendations for future study is to establish an 
epidemiological process to examine the prostate cancer risk in the male population by a 
common and more accurate test. There should be methods of surveillance of the disease 
at an early stage to improve an early detection of prostate cancer. Health professionals 
should inform males about the benefits of prostate cancer genetic screening.  
Statistical Methods Recommendations 
A meta-analysis is a complicated technique. Published papers and books 




meta-analysis studies of this hypothesis; each study had a different point regarding this 
type of design. Bai et al. (2009) included seven studies on only the MTHFR gene and its 
two polymorphisms C677T and A1298C. Li et al. (2011) included nine studies and 
examined only the MTHFR gene and its A1298C Polymorphism. Zhang et al. (2012) 
included 15 individual studies in his study, but the assumption of independence between 
the studies for a meta-analysis was not reached in his study. Zhang et al. included the 
results of a meta-analysis study by Collin et al. (2009) as an individual study. 
The unit of meta-analysis is the included individual studies. This study included 
20 eligible studies to increase the sample size and provide a more accurate statistical 
analysis. The assumption of independence between studies was provided in this study. In 
future meta-analysis studies, researchers should increase the sample size to provide 
results that are more accurate. The weighting strategy, on studies with a different number 
of participants, is another statistical matter that should be addressed with future meta-
analyses.  
Recommendation for Policy Makers 
The job of a policy maker is to create a policy to protect people from health 
problems. The policy makers in public health infrastructure must establish policies to 
help people in developing a healthy lifestyle. The policy makers must promote better 
health care services, emergency services, and increase the life expectancy. The policy 




Improve the Tests 
One of the policies that should be implemented is to create improved tests for 
prostate cancer risk. There must be accurate tests that are affordable to all. Physicians and 
health professionals should inform the participant about the benefits and harms of the test 
based on the procedure by the policy. Policy makers should also improve prostate cancer 
diagnosis through genetic screening for prostate cancer.  
Insurance Coverage 
Insurance should cover the cost of testing for the disease without affecting the 
insurance premium cost. If the insurance company pays to diagnose prostate cancer at an 
early stage, then they will pay less compared to paying for developed prostate cancer 
treatment. The insurance company should cover the cost of course treatment for prostate 
cancer disease. Patients should not fear taking the test or informing their insurance 
company of the results.  
Psychological Policy 
Prostate cancer patients fear the progression of the disease, the stage of the 
disease, and the treatment course. Patients with prostate cancer may experience 
psychological stress, depression, pain, and anxiety (“Enhancing Your Quality of Life 
When You Have Advanced Prostate Cancer - Prostate Cancer Canada,” n.d.). Patients 
with prostate cancer may feel hopeless, helpless, a fear of death, and a lack of pleasure. 
An effective treatment and psychotherapy may assist patients in reducing their symptoms 
and better adjust to their treatment. An accurate test and insurance coverage may decrease 




this disease, including sections for the family. A team of patients, psychologists, and 
urologists can help the patient to manage the disease. 
Implications  
A successful public health program is one that improves the health of a population 
and increases the health literacy among them. Social change is based on the role of 
societal factors related to the etiology of prostate cancer. This study could lead to positive 
social change by providing information on how to improve individual knowledge 
regarding the disease and by promoting the awareness of prostate cancer. I also provided 
information on how to prevent, detect, and treat prostate cancer in the early stage of the 
disease by genetic screening. This early stage diagnosis helps to decrease the cost of 
treatment and increase the chance of surviving (Krahn et al., 2010). The increased health 
literacy and knowledge of prostate cancer could lead to a better understanding of the 
disease to protect males from the progression of prostate cancer.  
Genetic screening could be used to increase life expectancy. Health professionals 
must understand the process of prostate cancer genetic screening so that they can improve 
the surveillance system and increase the accuracy of the screening (Petersen, 2000). If 
more patients are informed about the benefits and harms of the genetic screening, public 
health workers may be able to better diagnose prostate cancer and provide better 
prevention and treatment strategies. 
Conclusion 
Genes play a role in diseases, especially in prostate cancer. In this study, I 




prostate cancer risk. Researchers have published different results on the association 
between MTHFR, MTR, and MTRR genes and prostate cancer; some scholars supported 
the association (Küçükhüseyin et al., 2011; ópez-Cortés et al., 2013) and some 
researchers did not find support for the association (Johansson et al., 2007; Stevens et al., 
2008). In this meta-analysis study, I combined the results of 20 eligible studies with a 
common hypothesis and an increased power of test to determine an association between 
MTHFR, MTR, and MTRR genes and prostate cancer risk. 
I concluded that gene and prostate cancer risk have a significant association, and 
the region of the target population may influence this association. I found a highly 
significant association between variant Allele T of polymorphism C667T in the MTHFR 
Gene and a decreased risk of prostate cancer. The TT genotype, and the recessive model 
(TT vs. [CT+CC)]), in polymorphism C667T of MTHFR Gene had a significant 
association with a decrease in the risk of prostate cancer. The Genotype AC in A1298C 
polymorphism of MTHFR Gene had a significant association with an increased risk of 
prostate cancer, but only in the fixed effect model. There was a significant association 
between regions due to the association with prostate cancer on Genotype AC versus AA 
in A1298C polymorphism of the MTHFR Gene. 
In this study, I collected information from America, Europe, and Asia. Each 
region had a specific gene pool, which led to gene variation among each population. The 
carcinogens that cause prostate cancer slightly alter the genetic code in a male’s gene 
sequence. The different regions also had different habits, such as diet, smoking, or 




I concluded that there is a need for general and comprehensive health care 
policies on genetic screening of prostate cancer. The genetic screening could lead to a 
longer and healthier life for males. The genotype screening could help to prevent the 
progress of prostate cancer at an early stage and reduce the cost of course of treatment. 
The prevention of prostate cancer could also improve the quality of life for males and 
their families. The individual patient may go through a treatment program at an early 
stage and increase his chance of living. Economically, males who live longer can provide 
financial support for their families, for a longer period in their life. The results of this 
study could be used to improve the health of individuals and communities. 
I recommend that a genetic screening test should be created to diagnose prostate 
cancer risk among males at an early stage of the disease. I recommend that more research 
should be conducted in a variety of geographical regions with a variety of carcinogen 
factors to find the gene-gene and gene-environment interaction related to prostate cancer 
risk. A meta-analysis is an appropriate method to increase the power of the test and to get 
better results than an individual study. If policy makers promote genetic screening and it 
becomes an accurate and active test in the diagnosis of prostate cancer at an early stage of 
the disease, my study results could promote positive social change due to increased life 
expectancy among males. This increased life expectancy could benefit individuals, their 
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Appendix A: The Data Collected Summary of Prostate Cancer Risk Associated with 
selected genes, MTHFR, MTR, and MTRR 
Table A1 
Summary of Prostate Cancer Associated with MTHFR Gene and C677T Polymorphism, 
Allele, and Genotype Frequencies 
First 
Author 
Year Region Ethnicity Cases Controls 
C T CC CT TT Tota
l 
C T CC CT T
T 
Total 
Kimura 2000 Europe Caucasian 165 99 49 67 16 132 203 97 65 73 12 150 
Heijman
s 
2003 Europe Caucasian 25 17 8 9 4 21 112
7 
459 399 329 65 793 
Cicek 2004 America Caucasian 610 268 214 182 43 439 637 321 219 199 61 479 
Singal 2004 America Caucasian, 
African-
American 


















2006 Europe Caucasian 322 124 111 100 12 223 642 228 243 156 36 435 
Johanss
on 












868 801 612 12
8 
1541 
Reljic 2007 Europe Caucasian 124 66 38 48 9 95 41 33 8 25 4 37 
Marchal 2008 Europe Caucasian 238 126 67 104 11 182 269 139 96 77 31 204 
Stevens 2008 America Caucasian 146
1 









2009 Asia Caucasian 144 42 53 38 2 93 225 89 80 65 12 157 
Cai 2010 Asia Asian 237 197 58 121 38 217 206 234 45 116 59 220 
Safarine
jad 
2010 Asia Caucasian 249 99 86 77 11 174 461 235 153 155 40 348 
Wu 2010 Asia  Asian 346 90 139 68 11 218 619 253 221 177 38 436 
Kucukh
useyin 
2011 Asia Caucasian 85 25 32 21 2 55 66 34 18 30 2 50 
Kobayas
hi 
2012 America Caucasian 63 23 22 19 2 43 230 110 72 86 12 170 
Fard-
Esfahani 
2012 Asia Caucasian 91 43 29 33 5 67 103 47 32 39 4 75 
Jackson 2013 America African-
American 
  157 (+)45 202   164 (+)42 206 
Lopez-
Cortes 
2013 America Caucasian 
Spanish 
133 75 30 73 1 104 161 59 52 57 1 110 
De 
Vogal 



















2014 Asia Caucasian 57  27 3  30 74  34 6  40 







Summary of Prostate Cancer Associated with MTHFR Gene and A1298C Polymorphism, 




Year Region Ethnicity Cases Controls 
    A C AA AC CC Total A C AA AC CC Total 
Cicek 2004 America Caucasian 595 283 195 205 39 439 667 289 233 201 44 478 
Singal 2004 America Caucasian, 
African-
American 


















2006 Europe Caucasian 282 162 87 108 27 222 555 313 176 203 55 434 
Marchal 2008 Europe Caucasian 258 106 98 62 17 177 295 113 108 79 22 209 
Stevens 2008 America Caucasian 1480 728 481 518 10
5 




2009 Asia Caucasian 78 104 31 16 44 91 199 133 77 45 44 166 
Cai 2010 Asia  Asian 363 71 150 63 4 217 359 81 144 71 5 220 
Safarineja
d 
2010 Asia Caucasian 250 98 90 70 14 174 466 230 158 150 40 348 
Wu 2010 Asia Asian 346 90 138 70 10 218 709 163 287 135 14 436 
Jackson 2013 America African-
American 
  137 (+)62 199   151 (+)51 202 
Lopez-
Cortes 
2013 America Caucasian 
Spanish 
202 6 100 2 2 104 217 3 108 1 1 110 
 
Table A3 
Summary of Prostate Cancer Associated with MTR Gene and A2756G Polymorphism, 
Allele, and Genotype Frequencies 
First Author Year Region Ethnicity Cases Controls 
    A G AA AG GG Total A G AA AG GG Total 
Marchal 2008 Europe Caucasian 290 74 118 54 9 181 331 77 138 55 11 204 
Cai 2010 Asia Asian 397 37 185 27 5 217 405 35 188 29 3 220 
Jackson 2013 America African-
American 
  97 (+)102 199   99 (+)106 205 
Lopez-
Cortes 
2013 America Caucasian 
Spanish 







Summary of Prostate Cancer Associated with MTRR Gene and C677T Polymorphism, 
Allele, and Genotype Frequencies 
First Author Year Region Ethnicity Cases Controls 
    A G AA AG GG Total A G AA AG GG Total 
Marchal 2008 Europe Caucasian 181 183 38 105 39 182 203 205 46 111 47 204 
Cai 2010 Asia Asian 314 120 111 92 14 217 325 115 118 89 13 220 
Jackson 2013 America African-
American 
  111 (+)84 195   120 (+)83 203 
Lopez-Cortes 2013 America Caucasian 
Spanish 






Appendix B: The Summary of Statistical Analysis Association Between One-Carbon 




Genetic Model Fixed effect model Random effect model Homogeneity test 
  OR [95% CI] adjuste 
p-value 
OR [95% CI] adjuste 
p-value 




Allele T vs.C .92[.88,.97] .002 .91[.83,1] .15 39.95 0.001 57.45 
TT vs. CC .81[.73,.91] .001 .78[.66,.92] .01 23.79 .13 28.54 
CT vs. CC .97[.91,1.03] .34 .96[.83,1.12] .70 53.70 <.001** 66.48 
Recessive .83[.75,.92] 0.001 .79[.68,.93] .01 23.47 .134 27.57 




Allele C vs. A 1.04[.96,1.13] .72 1.06[.93,1.22] 1.00 19 .03* 52.63 
CC vs. AA 1.18[.98,1.41] .24 1.14[.89,1.46] 1.00 13.12 .16 31.40 
AC vs. AA 1.24[1.11,1.38] <.001** 1.10[.90,1.34] 1.00 22.88 .007* 60.66 
Recessive 1.07[.90,1.27] .72 1.07[.83,1.39] 1.00 15.19 .09 40.75 




Allele G vs. A 1.17[.89,1.54] 1.00 1.19[.86,1.65] 1.00 2.49 .29 19.68 
GG vs. AA 1.26[.61,2.62] 1.00 1.26[.61,2.62] 1.00 1.23 .54 Q<df 
AG vs. AA 1.13[.81,1.58] 1.00 1.13[.81,1.58] 1.00 1.43 .49 Q<df 
Recessive 1.22[.59,2.52] 1.00 1.22[.59,2.52] 1.00 1.29 .52 Q<df 




Allele G vs. A .95[.80,1.14] 1.00 .94[.75,1.18] 1.00 3.04 .22 34.32 
GG vs. AA .87[.55,1.38] 1.00 .70[.29,1.72] 1.00 6.10 .05 67.19 
AG vs. AA .97[.72,1.31] 1.00 .63[.25,1.58] 1.00 13.63 .001** 85.33 
Recessive 1[.68,1.44] 1.00 1[.68,1.44] 1.00 .33 .85 Q<df 





Appendix C: A Summary of Statistical Results from Individual Included Study on 














SNP Odds Ratios 
(95%CI) 







150 MTHFR C677T 
Crude 
CC Ref. 
CT 1.22 (0.74-2) 
TT 1.77 (0.77-4.08) 
Recessive 1.59 (0.72-3.49) 
Dominant 1.29 (0.80-2.09) 
T vs. C 1.25 (0.89-1.78) 
Heijman
s 







21 793 MTHFR C677T 
Crude 
CC Ref. 
CT 1.36 (0.52-3.57) 
TT 3.07 (0.90-10.48) 
Recessive 1.59 (0.72-3.49) 
Dominant 2.63 (0.86-8.06) 
T vs. C 1.67 (0.89-3.12) 








479 MTHFR C677T 
Crude 
CC Ref. 
CT 0.93 (0.71-1.23) 
TT 0.72 (0.47-1.11) 
Recessive 0.74 (0.49-1.12) 
Dominant 0.88 (0.68-1.15) 






AC 1.22 (0.93-1.6) 
CC 1.06(0.66-1.70) 
Recessive 0.96 (0.61-1.51) 
Dominant 1.19 (0.92-1.54) 
C vs. A 1.1 (0.90-1.34) 








81 42 MTHFR C677T 
Crude 
CC Ref. 
CT 0.51 (0.23-1.12) 
TT 1.43 (0.27-7.48) 
Recessive 1.89 (0.37-9.54) 
Dominant 0.59 (0.28-1.26) 






AC 1.56 (0.70-3.54) 
CC 0.80 (0.25-2.52) 
Recessive 0.62 (0.21-0.82) 
Dominant 1.34 (0.63-2.88) 
C vs. A 1.03 (0.60-1.78) 










CT 1.40 (1.00-1.96) 
TT 0.73 (0.36-1.46) 
Recessive 0.63 (0.32-1.24) 
Dominant 1.28 (0.92-1.76) 






AC 1.08 (0.76-1.52) 
CC 0.99 (0.59-1.68) 
Recessive 0.93 (0.74-1.17) 
Dominant 1.08 (0.95-1.22) 
C vs. A 1.02 (0.80-1.29) 
Johansso
n 








1541 MTHFR C677T 
Crude 
CC Ref. 
CT 1.10 (0.96-1.26) 
TT 0.98 (0.77-1.24) 
Recessive 0.93 (0.74-1.17) 
Dominant 1.08 (0.95-1.22) 
T vs. C 1.03 (0.94-1.14) 






95 37 MTHFR C677T 
Crude 
CC Ref. 
CT 0.40 (0.16-1.00) 
TT 0.47 (0.12-1.93) 
Recessive 0.86 (0.25-3.00) 
Dominant 0.41 (0.17-1.00) 
T vs. C 0.66 (0.38-1.14) 







204 MTHFR C677T 
Crude 
CC Ref. 
CT 1.93 (1.26-2.97) 
TT 0.51 (0.24-1.08) 
Recessive 0.36 (0.17-0.74) 
Dominant 1.53 (1.01-2.30) 





AC 0.86 (0.56-1.33) 
CC 0.85 (0.43-1.70) 
Recessive 0.90 (0.46-1.76) 
Dominant 0.86 (0.58-1.29) 
C vs. A 1.07 (0.78-1.47) 







204 MTR Crude 
A2756G 
AA Ref. 
AG 1.14 (0.73-1.80) 
GG 0.96 (0.38-2.39) 
Recessive 0.91 (0.37-2.27) 
Dominant 1.12 (0.73-1.70) 
G vs. A 1.10 (0.77-1.56) 







204 MTRR Crude 
A66G 
AA Ref. 
AG 1.14 (0.69-1.90) 
GG 1.00 (0.55-1.84) 
Recessive 1.10 (0.68-1.78) 




G vs. A 1.00 (0.75-1.33) 









1107 MTHFR C677T 
Crude 
CC Ref. 
CT 1.04 (0.87-1.24) 
TT 0.84 (0.64-1.12) 
Recessive 0.83 (0.63-1.08) 
Dominant 1.00 (0.84-1.18) 
T vs. C 0.96 (0.84-1.08) 
Musluma
noglu 





93 157 MTHFR C677T 
Crude 
CC Ref. 
CT 0.88 (0.52-1.50) 
TT 0.25 (0.05-1.17) 
Recessive 0.26 (0.06-1.21) 
Dominant 0.78 (0.47-1.31) 






AC 0.88 (0.43-1.79) 
CC 2.48 (1.38-4.48) 
Recessive 2.59 (1.52-4.44) 
Dominant 1.67 (0.98-2.84) 
A vs C 0.50 (0.35-0.72) 







220 MTHFR C677T 
Crude 
CC Ref. 
CT 0.81 (0.51-1.29) 
TT 0.50 (0.28-0.88) 
Recessive 0.58 (0.36-0.92) 
Dominant 0.70 (0.45-1.10) 






AC 0.85 (0.56-1.28) 
CC 0.77 (0.20-2.92) 
Recessive 0.81 (0.21-3.05) 
Dominant 0.85 (0.57-1.26) 
C vs A 0.87 (0.61-1.23) 












Recessive 1.7 (40-7.23) 
Dominant 1.02 (0.60-1.73) 
G vs A 1.08(0.67-1.75) 












Recessive 0.91 (0.42-1.98) 
Dominance 1.10 (0.76-
1.61) 
G vs A 1.08 (0.80-1.46) 
Safarinej
ad 














CT 0.88 (0.60-1.29) 
TT 0.49 (0.24-1.00) 
Recessive 0.52 (0.26-1.04) 
Dominant 0.80 (0.56-1.16) 






AC 0.82 (0.56-1.20) 
CC 0.61 (0.32-1.19) 
Recessive 0.67 (0.36-1.27) 
Dominant 0.78 (0.54-1.12) 
C vs A 0.79 (0.60-1.05) 
 







436 MTHFR Crude 
C677T 
CC Ref. 
CT 0.61 (0.43-0.87) 
TT 0.46 (0.23- 0.93) 
Recessive 0.56 (0.28-1.11) 
Dominant 0.58 (0.42-0.82) 









C vs. A 1.13(0.85-1.51) 
Kucukhu
seyin 






55 50 MTHFR C677T 
Crude 
CC Ref. 
CT 0.39 (0.18-0.88) 
TT 0.56 (0.07-4.34) 
Recessive 0.91 (0.12-6.68) 
Dominant 0.40 (0.18-0.89) 
T vs. C 0.57 (0.31-1.05) 
Kobayas
hi 





43 170 MTHFR C677T 
Crude 
CC Ref. 
CT 0.72 (0.36-1.44) 
TT 0.54 (0.11-2.62) 
Recessive 0.64 (0.14-2.98) 
Dominant 0.70 (0.36-1.37) 
T vs. C 0.76 (0.45-1.29) 
Fard-
Esfahani 





67 75 MTHFR C677T 
Crude 
CC Ref. 
CT 0.93 (0.47-1.85) 
TT 1.38 (0.34-5.63) 
Recessive 1.43 (0.37-5.57) 
Dominant 0.95 (0.49-1.85) 
T vs. C 1.03 (0.63-1.71) 




















































110 MTHFR Crude 
C677T 
CC Ref. 
CT 2.22 (1.26-3.91) 
TT 1.73 (.10- 28.73) 
Recessive 1.06 (0.06-
17.14) 
Dominant 2.21 (1.25-3.89) 





AC 2.16 (0.19-24.19) 





C vs. A 2.15 (0.53-8.7) 
Lopez-
Cortes 










110 MTR Crude 
A2756G 
AA Ref. 
AG 2.03 (0.66-6.29) 
GG 3.4 (0.35-33.17) 
Recessive 3.24 (0.33-
31.63) 
Dominant 2.26 (0.81-6.26) 
G vs. A 0.71 (0.48-1.04) 
Lopez-
Cortes 










110 MTRR Crude 
A66G 
AA Ref. 
AG 0.1 (0.03-0.35) 
GG 0.15 (0.03-0.66) 
Recessive 1.18 (0.48-2.91) 
Dominant 0.10 (0.03-0.36) 
G vs. A 2.36 (0.94-5.92) 
Kobayas
hi 





80 334 MTHFR C677T 
Crude 
CC Ref. 
CT 0.72 (0.36-1.44) 
TT 0.54 (. 11- 2.62) 
Recessive 0.64 (0.14-2.98) 
Dominant 0.70 (. 36-1.37) 
T vs.C 0.76 (0.45-1.29) 
De 
Vogel 









2607 MTHFR C677T 
Crude 
CC Ref. 
CT 0.84 (0.74-0.94) 
TT 0.81 (0.68- 0.97) 
Recessive 0.87 (0.74-1.03) 
Dominant 0.83 (0.74-0.93) 
T vs.C 0.86 (0.79-0.94) 





30 40 MTHFR C677T 
Crude 
CC Ref. 
CT 0.63 (0.14-2.75) 
 
 
